<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - NEFAZODONE HYDROCHLORIDE- nefazodone
hydrochloride tablet</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">NEFAZODONE HYDROCHLORIDE-
nefazodone hydrochloride tablet<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ANEFAZODONE%20HYDROCHLORIDE%2D%20Nefazodone%20Hydrochloride%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Db1d149db%2Dad43%2D4f3f%2Daef1%2Dfb0395ba4191%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a class="tip" rel="tooltip" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects."
href="#boxedwarning">Boxed Warnings</a></li>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22nefazodone%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=nefazodone"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=nefazodone"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=nefazodone[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=nefazodone/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=nefazodone/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=nefazodone/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=nefazodone[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00402&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">63304-541-05, 63304-541-30, 63304-542-05,
63304-542-30, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id="item-code-s"><span>63304-543-05,
63304-543-30, 63304-544-05, 63304-544-30, 63304-545-05,
63304-545-30</span></span></div>
</li>
<li><strong>Packager:</strong> Ranbaxy Pharmaceuticals Inc.</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status"></span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated December 24, 2008</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191&amp;type=pdf&amp;name=b1d149db-ad43-4f3f-aef1-fb0395ba4191"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191&amp;type=zip&amp;name=NEFAZODONE%20HYDROCHLORIDE"
target="_blank">XML</a></li>
<li class="medguide">Medication Guide: <a href=
"/dailymed/medguide.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191"
target="_blank">HTML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip"
rel="tooltip" href="#" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What
is this?)</a>
<div class="Warning toggle-content open"><a name=
"INV-cb19208c-f611-40bc-ac80-67a31b818065" id=
"INV-cb19208c-f611-40bc-ac80-67a31b818065"></a> <a name="section-3"
id="section-3"></a>
<p class="First"><a name="INV-eb08ba3d-7357-46d9-8af2-c57f116f0226"
id="INV-eb08ba3d-7357-46d9-8af2-c57f116f0226"></a><span class=
"Bold">Suicidality and Antidepressant Drugs</span></p>
<p><a name="INV-9fd56398-e9bf-4412-b371-5de81f657116" id=
"INV-9fd56398-e9bf-4412-b371-5de81f657116"></a><span class=
"Bold">Antidepressants increased the risk compared to placebo of
suicidal thinking and behavior (suicidality) in children,
adolescents, and young adults in short-term studies of major
depressive disorder (MDD) and other psychiatric disorders. Anyone
considering the use of nefazodone hydrochloride tablets or any
other antidepressant in a child, adolescent, or young adult must
balance this risk with the clinical need. Short-term studies did
not show an increase in the risk of suicidality with
antidepressants compared to placebo in adults beyond age 24; there
was a reduction in risk with antidepressants compared to placebo in
adults aged 65 and older. Depression and certain other psychiatric
disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant
therapy should be monitored appropriately and observed closely for
clinical worsening, suicidality, or unusual changes in behavior.
Families and caregivers should be advised of the need for close
observation and communication with the prescriber. Nefazodone
hydrochloride tablets are not approved for use in pediatric
patients. (See WARNINGS, Clinical Worsening and Suicide Risk;
PRECAUTIONS, Information for Patients; and PRECAUTIONS, Pediatric
Use.)</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li id="boxedwarning"><a href="#">BOXED WARNING</a>
<div class="Warning toggle-content open"><a name=
"INV-6fce62fa-1c18-408c-8a05-bc3d5b867d63" id=
"INV-6fce62fa-1c18-408c-8a05-bc3d5b867d63"></a> <a name="section-4"
id="section-4"></a>
<p class="First"><a name="INV-0e8b2223-9f42-433a-b97d-bffac6cef1f6"
id="INV-0e8b2223-9f42-433a-b97d-bffac6cef1f6"></a><span class=
"Bold">Warning</span></p>
<p><a name="INV-02e54e8f-1ecb-4ce4-8553-dd21a2bb2b1c" id=
"INV-02e54e8f-1ecb-4ce4-8553-dd21a2bb2b1c"></a><span class=
"Bold">Cases of life-threatening hepatic failure have been reported
in patients treated with nefazodone hydrochloride tablets. The
reported rate in the United States is about 1 case of liver failure
resulting in death or transplant per 250,000 to</span> <span class=
"Bold">300,000 patient-years of nefazodone hydrochloride treatment.
The total patient-years is a summation of each patient’s duration
of exposure expressed in years. For example, 1 patient-year is
equal to 2 patients each treated for 6 months, 3 patients each
treated for 4 months, etc. (See WARNINGS.)</span></p>
<p><a name="INV-ff5337c4-8b7c-44cd-a62a-fa052cb0a961" id=
"INV-ff5337c4-8b7c-44cd-a62a-fa052cb0a961"></a><span class=
"Bold">Ordinarily, treatment with nefazodone hydrochloride tablets
should not be initiated in individuals with active liver disease or
with elevated baseline serum transaminases. There is no evidence
that pre-existing liver disease increases the likelihood of
developing liver failure, however, baseline abnormalities can
complicate patient monitoring.</span></p>
<p><a name="INV-c85c6e8f-fc2e-41a5-bde2-a172c54c70d4" id=
"INV-c85c6e8f-fc2e-41a5-bde2-a172c54c70d4"></a><span class=
"Bold">Patients should be advised to be alert for signs and
symptoms of liver dysfunction (jaundice, anorexia, gastrointestinal
complaints, malaise, etc.) and to report them to their doctor
immediately if they occur.</span></p>
<p><a name="INV-a41a34d2-1edd-456b-8f82-633f0da997aa" id=
"INV-a41a34d2-1edd-456b-8f82-633f0da997aa"></a><span class=
"Bold">Nefazodone hydrochloride tablets should be discontinued if
clinical signs or symptoms suggest liver failure (see PRECAUTIONS,
Information for Patients). Patients who develop evidence of
hepatocellular injury such as increased serum AST or serum ALT
levels ≥ 3 times the upper limit of NORMAL, while on nefazodone
hydrochloride tablets should be withdrawn from the drug. These
patients should be presumed to be at increased risk for liver
injury if nefazodone hydrochloride is reintroduced. Accordingly,
such patients should not be considered for re-treatment.</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">- Section Title Not Found In Database</a>
<div class="Section toggle-content closed"><a name=
"INV-cbda1ac6-3317-4754-841d-e79b7673afaa" id=
"INV-cbda1ac6-3317-4754-841d-e79b7673afaa"></a> <a name="section-2"
id="section-2"></a>
<p class="First"><a name="INV-20f337f3-16b8-4b62-9707-b464c60270cb"
id="INV-20f337f3-16b8-4b62-9707-b464c60270cb"></a><span class=
"Bold">Rx only</span></p>
<p><a name="INV-9e2ce63c-7e53-41f3-ba0c-d89b55f4eb0a" id=
"INV-9e2ce63c-7e53-41f3-ba0c-d89b55f4eb0a"></a><span class=
"Bold">(Patient Information Included)</span></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">SPL UNCLASSIFIED SECTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"42229-5"><a name="INV-19f66161-45ba-46e5-9cf9-4a18a24549d8" id=
"INV-19f66161-45ba-46e5-9cf9-4a18a24549d8"></a> <a name="section-3"
id="section-3"></a>
<p class="First"><a name="INV-88e96413-d162-42c3-8372-9617a06a03b7"
id="INV-88e96413-d162-42c3-8372-9617a06a03b7"></a>Before
prescribing nefazodone hydrochloride tablets, the physician should
be thoroughly familiar with the details of this prescribing
information.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="INV-485dfabd-8929-4da4-9b03-ef15cf9cea93" id=
"INV-485dfabd-8929-4da4-9b03-ef15cf9cea93"></a> <a name="section-4"
id="section-4"></a>
<p class="First"><a name="INV-547bf6fe-b8cb-456b-9c74-42e3535b5c68"
id="INV-547bf6fe-b8cb-456b-9c74-42e3535b5c68"></a>Nefazodone
hydrochloride tablets, USP is an antidepressant for oral
administration with a chemical structure unrelated to selective
serotonin reuptake inhibitors, tricyclics, tetracyclics, or
monoamine oxidase inhibitors (MAOI).</p>
<p><a name="INV-6118c246-e283-4825-8616-ebdbab1f3134" id=
"INV-6118c246-e283-4825-8616-ebdbab1f3134"></a>Nefazodone
hydrochloride, USP is a synthetically derived phenylpiperazine
antidepressant. The chemical name for nefazodone hydrochloride is
2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one
monohydrochloride. The molecular formula is C <span class=
"Sub">25</span>H<span class="Sub">32</span>ClN<span class=
"Sub">5</span>O<span class="Sub">2</span> • HCl, which corresponds
to a molecular weight of 506.5. The structural formula is:</p>
<div class="Figure"><img src=
"image.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191&amp;name=image_1.JPG"
alt=""></div>
<p><a name="INV-762e6376-b7a6-49d7-86d3-b97bcc68f6d1" id=
"INV-762e6376-b7a6-49d7-86d3-b97bcc68f6d1"></a>Nefazodone
hydrochloride, USP is a nonhygroscopic, white crystalline solid. It
is freely soluble in chloroform, soluble in propylene glycol, and
slightly soluble in polyethylene glycol and water.</p>
<p><a name="INV-fb8037d5-67e9-45c2-a40a-7ba56f97419e" id=
"INV-fb8037d5-67e9-45c2-a40a-7ba56f97419e"></a>Nefazodone
hydrochloride tablets, USP is supplied as uncoated round tablets
containing either 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg of
nefazodone hydrochloride, USP and the following inactive
ingredients: colloidal silicon dioxide, ferric oxide (red and/or
yellow) as colorants for (50 mg, 150 mg, and 200 mg strengths
only), magnesium stearate, microcrystalline cellulose, povidone and
sodium starch glycolate.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="INV-5cebd3cc-eca1-44cd-b974-0cf9abc6f40c" id=
"INV-5cebd3cc-eca1-44cd-b974-0cf9abc6f40c"></a> <a name="section-5"
id="section-5"></a>
<p class="First"><a name="INV-d2989e0d-e7b7-4423-9146-0a2399923d29"
id="INV-d2989e0d-e7b7-4423-9146-0a2399923d29"></a><span class=
"Bold">Pharmacodynamics</span></p>
<p><a name="INV-aa39a9ac-2d44-481a-9864-a8eac8f5ff1d" id=
"INV-aa39a9ac-2d44-481a-9864-a8eac8f5ff1d"></a>The mechanism of
action of nefazodone, as with other antidepressants, is
unknown.</p>
<p><a name="INV-2c4ec3ed-e340-4705-8344-e77d3d799dc8" id=
"INV-2c4ec3ed-e340-4705-8344-e77d3d799dc8"></a>Preclinical studies
have shown that nefazodone inhibits neuronal uptake of serotonin
and norepinephrine.</p>
<p><a name="INV-1f0f6e77-e96e-4294-9f42-c966ed79acdb" id=
"INV-1f0f6e77-e96e-4294-9f42-c966ed79acdb"></a>Nefazodone occupies
central 5-HT <span class="Sub">2</span> receptors at nanomolar
concentrations, and acts as an antagonist at this receptor.
Nefazodone was shown to antagonize alpha<span class=
"Sub">1</span>-adrenergic receptors, a property which may be
associated with postural hypotension. <span class="Italics">In
vitro</span> binding studies showed that nefazodone had no
significant affinity for the following receptors: alpha<span class=
"Sub">2</span> and beta adrenergic, 5-HT<span class=
"Sub">1A</span>, cholinergic, dopaminergic, or benzodiazepine.</p>
<p><a name="INV-9a590483-1716-49dd-bc9a-5dfe476dbed0" id=
"INV-9a590483-1716-49dd-bc9a-5dfe476dbed0"></a><span class=
"Bold">Pharmacokinetics</span></p>
<p><a name="INV-54bace13-32ec-4859-bb1f-5007b116ec4e" id=
"INV-54bace13-32ec-4859-bb1f-5007b116ec4e"></a>Nefazodone
hydrochloride is rapidly and completely absorbed but is subject to
extensive metabolism, so that its absolute bioavailability is low,
about 20%, and variable. Peak plasma concentrations occur at about
one hour and the half-life of nefazodone is 2 to 4 hours.</p>
<p><a name="INV-7b820e41-0773-4ab6-97dc-7d71520e769a" id=
"INV-7b820e41-0773-4ab6-97dc-7d71520e769a"></a>Both nefazodone and
its pharmacologically similar metabolite, hydroxynefazodone,
exhibit nonlinear kinetics for both dose and time, with AUC and C
<span class="Sub">max</span> increasing more than proportionally
with dose increases and more than expected upon multiple dosing
over time, compared to single dosing. For example, in a
multiple-dose study involving BID dosing with 50, 100, and 200 mg,
the AUC for nefazodone and hydroxynefazodone increased by about
4-fold with an increase in dose from 200 to 400 mg per day;
C<span class="Sub">max</span> increased by about 3-fold with the
same dose increase. In a multiple-dose study involving BID dosing
with 25, 50, 100, and 150 mg, the accumulation ratios for
nefazodone and hydroxynefazodone AUC, after 5 days of BID dosing
relative to the first dose, ranged from approximately 3 to 4 at the
lower doses (50 to 100 mg/day) and from 5 to 7 at the higher doses
(200 to 300 mg/day); there were also approximately 2- to 4-fold
increases in C<span class="Sub">max</span> after 5 days of BID
dosing relative to the first dose, suggesting extensive and greater
than predicted accumulation of nefazodone and its hydroxy
metabolite with multiple dosing. Steady-state plasma nefazodone and
metabolite concentrations are attained within 4 to 5 days of
initiation of BID dosing or upon dose increase or decrease.</p>
<p><a name="INV-1ee330c7-9e7f-424e-9b05-9c03716ca88a" id=
"INV-1ee330c7-9e7f-424e-9b05-9c03716ca88a"></a>Nefazodone is
extensively metabolized after oral administration by n-dealkylation
and aliphatic and aromatic hydroxylation, and less than 1% of
administered nefazodone is excreted unchanged in urine. Attempts to
characterize three metabolites identified in plasma,
hydroxynefazodone (HO-NEF), meta-chlorophenylpiperazine (mCPP), and
a triazole-dione metabolite, have been carried out. The AUC
(expressed as a multiple of the AUC for nefazodone dosed at 100 mg
BID) and elimination half-lives for these three metabolites were as
follows:</p>
<a name="INV-21dbe49e-7493-4235-ab0d-f28455a67098" id=
"INV-21dbe49e-7493-4235-ab0d-f28455a67098"></a>
<div class="scrollingtable">
<table border="1" frame="border">
<colgroup>
<col width="232px">
<col width="188px">
<col width="184px"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" colspan="3">AUC
Multiples and T<span class="Sub">½</span> for Three Metabolites of
Nefazodone (100 mg BID)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">Metabolite</td>
<td class="Botrule" align="center">AUC Multiples</td>
<td class="Botrule Rrule" align="center">T <span class=
"Sub">½</span></td>
</tr>
<tr>
<td class="Botrule Lrule">HO-NEF</td>
<td class="Botrule" align="center">0.4</td>
<td class="Botrule Rrule" align="center">1.5 to 4 h</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">mCPP</td>
<td class="Botrule" align="center">0.07</td>
<td class="Botrule Rrule" align="center">4 to 8 h</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">Triazole-dione</td>
<td class="Botrule" align="center">4</td>
<td class="Botrule Rrule" align="center">18 h</td>
</tr>
</tbody>
</table>
</div>
<p><a name="INV-f17e2c34-a579-493e-b827-77fee469bfee" id=
"INV-f17e2c34-a579-493e-b827-77fee469bfee"></a>HO-NEF possesses a
pharmacological profile qualitatively and quantitatively similar to
that of nefazodone. mCPP has some similarities to nefazodone, but
also has agonist activity at some serotonergic receptor subtypes.
The pharmacological profile of the triazole-dione metabolite has
not yet been well characterized. In addition to the above
compounds, several other metabolites were present in plasma but
have not been tested for pharmacological activity.</p>
<p><a name="INV-5461ede0-83f9-480f-b9fc-5e7f1bcaf8f3" id=
"INV-5461ede0-83f9-480f-b9fc-5e7f1bcaf8f3"></a>After oral
administration of radiolabeled nefazodone, the mean half-life of
total label ranged between 11 and 24 hours. Approximately 55% of
the administered radioactivity was detected in urine and about 20
to 30% in feces.</p>
<p><a name="INV-97fe209d-f81f-412a-bae9-79fe70e861f8" id=
"INV-97fe209d-f81f-412a-bae9-79fe70e861f8"></a><span class=
"Italics">Distribution</span>—Nefazodone is widely distributed in
body tissues, including the central nervous system (CNS). In humans
the volume of distribution of nefazodone ranges from 0.22 to 0.87
L/kg.</p>
<p><a name="INV-ad183197-b510-4fd1-876b-9da4b175622f" id=
"INV-ad183197-b510-4fd1-876b-9da4b175622f"></a><span class=
"Italics">Protein Binding</span>—At concentrations of 25 to 2500
ng/mL nefazodone is extensively (&gt; 99%) bound to human plasma
proteins <span class="Italics">in vitro</span>. The administration
of 200 mg BID of nefazodone for 1 week did not increase the
fraction of unbound warfarin in subjects whose prothrombin times
had been prolonged by warfarin therapy to 120 to 150% of the
laboratory control (see <span class="Bold">PRECAUTIONS, Drug
Interactions).</span> While nefazodone did not alter the
<span class="Italics">in vitro</span> protein binding of
chlorpromazine, desipramine, diazepam, diphenylhydantoin,
lidocaine, prazosin, propranolol, or verapamil, it is unknown
whether displacement of either nefazodone or these drugs occurs
<span class="Italics">in vivo</span>. There was a 5% decrease in
the protein binding of haloperidol; this is probably of no clinical
significance.</p>
<p><a name="INV-0e399e30-70a6-43c8-989c-493393237ae1" id=
"INV-0e399e30-70a6-43c8-989c-493393237ae1"></a><span class=
"Italics">Effect of Food</span>—Food delays the absorption of
nefazodone and decreases the bioavailability of nefazodone by
approximately 20%.</p>
<p><a name="INV-73989aeb-a540-4fb9-86a2-5569329bf25b" id=
"INV-73989aeb-a540-4fb9-86a2-5569329bf25b"></a><span class=
"Italics">Renal Disease</span>—In studies involving 29 renally
impaired patients, renal impairment (creatinine clearances ranging
from 7 to 60 mL/min/1.73 m <span class="Sup">2</span>) had no
effect on steady-state nefazodone plasma concentrations.</p>
<p><a name="INV-9d3e3aa6-fedc-49cf-a39c-200fd715641c" id=
"INV-9d3e3aa6-fedc-49cf-a39c-200fd715641c"></a><span class=
"Italics">Liver Disease</span>—In a multiple-dose study of patients
with liver cirrhosis, the AUC values for nefazodone and HO-NEF at
steady state were approximately 25% greater than those observed in
normal volunteers.</p>
<p><a name="INV-58eb2d84-33e8-4abc-a60c-d1208354a064" id=
"INV-58eb2d84-33e8-4abc-a60c-d1208354a064"></a><span class=
"Italics">Age/Gender Effects</span>—After single doses of 300 mg to
younger (18 to 45 years) and older patients (&gt; 65 years), C
<span class="Sub">max</span> and AUC for nefazodone and
hydroxynefazodone were up to twice as high in the older patients.
With multiple doses, however, differences were much smaller, 10 to
20%. A similar result was seen for gender, with a higher
C<span class="Sub">max</span> and AUC in women after single doses
but no difference after multiple doses.</p>
<p><a name="INV-323627c0-624a-43ed-bf50-b48e92e853c6" id=
"INV-323627c0-624a-43ed-bf50-b48e92e853c6"></a>Treatment with
nefazodone should be initiated at half the usual dose in elderly
patients, especially women (see <span class="Bold">DOSAGE AND
ADMINISTRATION</span>), but the therapeutic dose range is similar
in younger and older patients.</p>
<p><a name="INV-0314d1d0-f319-48a4-a44b-819efc49f8c8" id=
"INV-0314d1d0-f319-48a4-a44b-819efc49f8c8"></a><span class=
"Bold">Clinical Efficacy Trial Results</span></p>
<p><a name="INV-3ef0f8fc-cd11-4ebf-ac8a-da46ed9d7265" id=
"INV-3ef0f8fc-cd11-4ebf-ac8a-da46ed9d7265"></a><span class=
"Italics">Studies in Outpatients with Depression</span></p>
<p><a name="INV-a959385a-1d8f-4a6c-b6ef-0ced4db07bc6" id=
"INV-a959385a-1d8f-4a6c-b6ef-0ced4db07bc6"></a>During its
premarketing development, the efficacy of nefazodone was evaluated
at doses within the therapeutic range in five well-controlled,
short-term (6 to 8 weeks’) clinical investigations. These trials
enrolled outpatients meeting DSM-III or DSM-IIIR criteria for major
depression. Among these trials, two demonstrated the effectiveness
of nefazodone, and two provided additional support for that
conclusion.</p>
<p><a name="INV-727eb483-32c0-48da-9020-1a88e3eea69e" id=
"INV-727eb483-32c0-48da-9020-1a88e3eea69e"></a>One trial was a
6-week dose-titration study comparing nefazodone in two dose ranges
(up to 300 mg/day and up to 600 mg/day [mean modal dose for this
group was about 400 mg/day], on a BID schedule) and placebo. The
second trial was an 8-week dose-titration study comparing
nefazodone (up to 600 mg/day; mean modal dose was 375 mg/day),
imipramine (up to 300 mg/day), and placebo, all on a BID schedule.
Both studies demonstrated nefazodone, at doses titrated between 300
mg to 600 mg/day (therapeutic dose range), to be superior to
placebo on at least three of the following four measures: 17-Item
Hamilton Depression Rating Scale or HDRS (total score), Hamilton
Depressed Mood item, Clinical Global Impressions (CGI) Severity
score, and CGI Improvement score. Significant differences were also
found for certain factors of the HDRS (e.g., anxiety factor, sleep
disturbance factor, and retardation factor). In the two supportive
studies, nefazodone was titrated up to 500 or 600 mg/day (mean
modal doses of 462 mg/day and 363 mg/day). In the fifth study, the
differentiation in response rates between nefazodone and placebo
was not statistically significant. Three additional trials were
conducted using subtherapeutic doses of nefazodone.</p>
<p><a name="INV-9cfd6740-00ad-4f63-aaac-6f330b4ea4bf" id=
"INV-9cfd6740-00ad-4f63-aaac-6f330b4ea4bf"></a>Overall,
approximately two thirds of patients in these trials were women,
and an analysis of the effects of gender on outcome did not suggest
any differential responsiveness on the basis of sex. There were too
few elderly patients in these trials to reveal possible age-related
differences in response.</p>
<p><a name="INV-36bbeeb4-d7ed-4cc8-8473-83d49daa76f9" id=
"INV-36bbeeb4-d7ed-4cc8-8473-83d49daa76f9"></a>Since its initial
marketing as an antidepressant drug product, additional clinical
investigations of nefazodone have been conducted. These studies
explored nefazodone’s use under conditions not evaluated fully at
the time initial marketing approval was granted.</p>
<p><a name="INV-c5fbf4cf-15d5-4b6c-81f3-70e7e6673440" id=
"INV-c5fbf4cf-15d5-4b6c-81f3-70e7e6673440"></a><span class=
"Italics">Studies in “Inpatients”</span></p>
<p><a name="INV-810df86f-85d6-4b49-a87b-38b7c77fbf3e" id=
"INV-810df86f-85d6-4b49-a87b-38b7c77fbf3e"></a>Two studies were
conducted to evaluate nefazodone’s effectiveness in hospitalized
depressed patients. These were 6-week, dose-titration trials
comparing nefazodone (up to 600 mg/day) and placebo, on a BID
schedule. In one study, nefazodone was superior to placebo. In this
study, the mean modal dose of nefazodone was 503 mg/day, and 85% of
these inpatients were melancholic; at baseline, patients were
distributed at the higher end of the 7-point CGI Severity scale, as
follows: 4= moderately ill (17%); 5 = markedly ill (48%); 6 =
severely ill (32%). In the other study, the differentiation in
response rates between nefazodone and placebo was not statistically
significant.This result may be explained by the “high” rate of
spontaneous improvement among the patients randomized to
placebo.</p>
<p><a name="INV-882dbb0f-3f84-445a-8083-7f025a67cba4" id=
"INV-882dbb0f-3f84-445a-8083-7f025a67cba4"></a><span class=
"Italics">Studies of “Relapse Prevention in Patients Recently
Recovered (Clinically) from Depression”</span></p>
<p><a name="INV-c84b4dd0-0d57-4cd4-ac0d-e52e259d62c5" id=
"INV-c84b4dd0-0d57-4cd4-ac0d-e52e259d62c5"></a>Two studies were
conducted to assess nefazodone’s capacity to maintain a clinical
remission in acutely depressed patients who were judged to have
responded adequately (HDRS total score ≤ 10) after a 16-week period
of open treatment with nefazodone (titration up to 600 mg/day). In
one study, nefazodone was superior to placebo. In this study,
patients (n = 131) were randomized to continuation on nefazodone or
placebo for an additional 36 weeks (1 year total). This study
demonstrated a significantly lower relapse rate (HDRS total score ≤
18) for patients taking nefazodone compared to those on placebo.
The second study was of appropriate design and power, but the
sample of patients admitted for evaluation did not suffer relapses
at a high enough incidence to provide a meaningful test of
nefazodone’s efficacy for this use.</p>
<p><a name="INV-e4d449bc-fef4-4f43-9f06-b5a505dcbc0c" id=
"INV-e4d449bc-fef4-4f43-9f06-b5a505dcbc0c"></a><span class=
"Italics">Comparisons of Clinical Trial Results</span></p>
<p><a name="INV-6cb050eb-97bb-4dcf-baf2-6a350254d80e" id=
"INV-6cb050eb-97bb-4dcf-baf2-6a350254d80e"></a>Highly variable
results have been seen in the clinical development of all
antidepressant drugs. Furthermore, in those circumstances when the
drugs have not been studied in the same controlled clinical
trial(s), comparisons among the findings of studies evaluating the
effectiveness of different antidepressant drug products are
inherently unreliable. Because conditions of testing (e.g., patient
samples, investigators, doses of the treatments administered and
compared, outcome measures, etc.) vary among trials, it is
virtually impossible to distinguish a difference in drug effect
from a difference due to one or more of the confounding factors
just enumerated.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="INV-bc05c6eb-2527-4535-994d-41b53848ca61" id=
"INV-bc05c6eb-2527-4535-994d-41b53848ca61"></a> <a name="section-6"
id="section-6"></a>
<p class="First"><a name="INV-caf42796-067e-4387-91c9-7c5f6561f243"
id="INV-caf42796-067e-4387-91c9-7c5f6561f243"></a>Nefazodone
hydrochloride tablets, USP is indicated for the treatment of
depression. When deciding among the alternative treatments
available for this condition, the prescriber should consider the
risk of hepatic failure associated with nefazodone hydrochloride
tablets, USP treatment (see <span class="Bold">WARNINGS</span>). In
many cases, this would lead to the conclusion that other drugs
should be tried first.</p>
<p><a name="INV-e7a6dc35-2f27-4e92-a9f0-cc5ce835a68a" id=
"INV-e7a6dc35-2f27-4e92-a9f0-cc5ce835a68a"></a>The efficacy of
nefazodone in the treatment of depression was established in 6 to 8
week controlled trials of outpatients and in a 6-week controlled
trial of depressed inpatients whose diagnoses corresponded most
closely to the DSM-III or DSM-IIIR category of major depressive
disorder (see <span class="Bold">CLINICAL PHARMACOLOGY</span>).</p>
<p><a name="INV-5f5f4e02-cca8-41f8-a4fe-a51492c5bf76" id=
"INV-5f5f4e02-cca8-41f8-a4fe-a51492c5bf76"></a>A major depressive
episode implies a prominent and relatively persistent depressed or
dysphoric mood that usually interferes with daily functioning
(nearly every day for at least 2 weeks). It must include either
depressed mood or loss of interest or pleasure and at least five of
the following nine symptoms: depressed mood, loss of interest in
usual activities, significant change in weight and/or appetite,
insomnia or hypersomnia, psychomotor agitation or retardation,
increased fatigue, feelings of guilt or worthlessness, slowed
thinking or impaired concentration, a suicide attempt or suicidal
ideation.</p>
<p><a name="INV-b95064a6-9f9d-4861-ae5c-dd690e122170" id=
"INV-b95064a6-9f9d-4861-ae5c-dd690e122170"></a>The efficacy of
nefazodone in reducing relapse in patients with major depression
who were judged to have had a satisfactory clinical response to 16
weeks of open-label nefazodone treatment for an acute depressive
episode has been demonstrated in a randomized placebo-controlled
trial (see <span class="Bold">CLINICAL PHARMACOLOGY</span>).
Although remitted patients were followed for as long as 36 weeks in
the study cited (i.e., 52 weeks total), the physician who elects to
use nefazodone for extended periods should periodically reevaluate
the long-term usefulness of the drug for the individual
patient.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="INV-1d8c2177-e18b-44ae-ae6a-10a5f40d6b5d" id=
"INV-1d8c2177-e18b-44ae-ae6a-10a5f40d6b5d"></a> <a name="section-7"
id="section-7"></a>
<p class="First"><a name="INV-232e4ff8-11a2-49cd-9ae9-ab810b109d60"
id="INV-232e4ff8-11a2-49cd-9ae9-ab810b109d60"></a>Coadministration
of terfenadine, astemizole, cisapride, pimozide, or carbamazepine
with nefazodone hydrochloride is contraindicated (see <span class=
"Bold">WARNINGS</span> and <span class=
"Bold">PRECAUTIONS</span>).</p>
<p><a name="INV-10a2398b-9f4f-4fd8-b72f-1fb9aece1b8d" id=
"INV-10a2398b-9f4f-4fd8-b72f-1fb9aece1b8d"></a>Nefazodone tablets
are contraindicated in patients who were withdrawn from nefazodone
because of evidence of liver injury (see <span class="Bold">BOXED
WARNING</span>). Nefazodone tablets are also contraindicated in
patients who have demonstrated hypersensitivity to nefazodone
hydro-chloride, its inactive ingredients, or other phenylpiperazine
antidepressants.</p>
<p><a name="INV-d868c380-72d1-4ef6-a31c-9bff86b53531" id=
"INV-d868c380-72d1-4ef6-a31c-9bff86b53531"></a>The coadministration
of triazolam and nefazodone causes a significant increase in the
plasma level of triazolam (see <span class="Bold">WARNINGS</span>
and <span class="Bold">PRECAUTIONS</span>), and a 75% reduction in
the initial triazolam dosage is recommended if the two drugs are to
be given together. Because not all commercially available dosage
forms of triazolam permit a sufficient dosage reduction, the
coadministration of triazolam and nefazodone should be avoided for
most patients, including the elderly.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">WARNINGS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34071-1"><a name="INV-8b18ea63-ef95-4cb3-95b9-2e20bdf1d9e3" id=
"INV-8b18ea63-ef95-4cb3-95b9-2e20bdf1d9e3"></a> <a name="section-8"
id="section-8"></a>
<p class="First"><a name="INV-51a6aad1-b8a6-4c8c-98f3-f095f05dbf9f"
id="INV-51a6aad1-b8a6-4c8c-98f3-f095f05dbf9f"></a><span class=
"Bold">Clinical Worsening and Suicide Risk</span></p>
<p><a name="INV-4fb7ad85-a4a1-47f0-937a-836aaa2ee841" id=
"INV-4fb7ad85-a4a1-47f0-937a-836aaa2ee841"></a>Patients with major
depressive disorder (MDD), both adult and pediatric, may experience
worsening of their depression and/or the emergence of suicidal
ideation and behavior (suicidality) or unusual changes in behavior,
whether or not they are taking antidepressant medications, and this
risk may persist until significant remission occurs. Suicide is a
known risk of depression and certain other psychiatric disorders,
and these disorders themselves are the strongest predictors of
suicide. There has been a long-standing concern, however, that
antidepressants may have a role in inducing worsening of depression
and the emergence of suicidality in certain patients during the
early phases of treatment. Pooled analyses of short-term
placebo-controlled trials of antidepressant drugs (SSRIs and
others) showed that these drugs increase the risk of suicidal
thinking and behavior (suicidality) in children, adolescents, and
young adults (ages 18 to 24) with major depressive disorder (MDD)
and other psychiatric disorders. Short-term studies did not show an
increase in the risk of suicidality with antidepressants compared
to placebo in adults beyond age 24; there was a reduction with
antidepressants compared to placebo in adults aged 65 and
older.</p>
<p><a name="INV-f4797bf6-269a-42a0-a30e-5c2a0ae47a56" id=
"INV-f4797bf6-269a-42a0-a30e-5c2a0ae47a56"></a>The pooled analyses
of placebo-controlled trials in children and adolescents with MDD,
obsessive compulsive disorder (OCD), or other psychiatric disorders
included a total of 24 short-term trials of 9 antidepressant drugs
in over 4400 patients. The pooled analyses of placebo-controlled
trials in adults with MDD or other psychiatric disorders included a
total of 295 short-term trials (median duration of 2 months) of 11
antidepressant drugs in over 77,000 patients. There was
considerable variation in risk of suicidality among drugs, but a
tendency toward an increase in the younger patients for almost all
drugs studied. There were differences in absolute risk of
suicidality across the different indications, with the highest
incidence in MDD. The risk differences (drug vs placebo), however,
were relatively stable within age strata and across indications.
These risk differences (drug-placebo difference in the number of
cases of suicidality per 1000 patients treated) are provided in
<span class="Bold">Table 1.</span></p>
<p><a name="INV-bc457aac-936f-440d-8ef1-ef0a1ced882e" id=
"INV-bc457aac-936f-440d-8ef1-ef0a1ced882e"></a><span class=
"Bold">Table 1</span></p>
<a name="INV-6e1937ec-215c-477d-913f-8d11447a1308" id=
"INV-6e1937ec-215c-477d-913f-8d11447a1308"></a>
<div class="scrollingtable">
<table border="1" frame="border">
<colgroup>
<col width="168px">
<col width="420px"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="center">Age Range</td>
<td class="Botrule Rrule" align="center">Drug-Placebo Difference in
Number of Cases of Suicidality per 1000 Patients Treated</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Rrule" align="center">Increases Compared to
Placebo</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">&lt; 18</td>
<td class="Botrule Rrule" align="center">14 additional cases</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">18 to 24</td>
<td class="Botrule Rrule" align="center">5 additional cases</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"></td>
<td class="Botrule Rrule" align="center">Decreases Compared to
Placebo</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center">25 to 64</td>
<td class="Botrule Rrule" align="center">1 fewer case</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">≥ 65</td>
<td class="Botrule Rrule" align="center">6 fewer cases</td>
</tr>
</tbody>
</table>
</div>
<p><a name="INV-fca63a49-17d1-4ff1-a5e7-b38d73c0760e" id=
"INV-fca63a49-17d1-4ff1-a5e7-b38d73c0760e"></a>No suicides occurred
in any of the pediatric trials. There were suicides in the adult
trials, but the number was not sufficient to reach any conclusion
about drug effect on suicide.</p>
<p><a name="INV-9dced4e3-9e56-448b-9960-2a2b6b51fab0" id=
"INV-9dced4e3-9e56-448b-9960-2a2b6b51fab0"></a>It is unknown
whether the suicidality risk extends to longer-term use, i.e.,
beyond several months. However, there is substantial evidence from
placebo-controlled maintenance trials in adults with depression
that the use of antidepressants can delay the recurrence of
depression.</p>
<p><a name="INV-9c735cb2-118f-4a67-9e4f-5b75fbed65c7" id=
"INV-9c735cb2-118f-4a67-9e4f-5b75fbed65c7"></a><span class=
"Bold">All patients being treated with antidepressants for any
indication should be monitored appropriately and observed closely
for clinical worsening, suicidality, and unusual changes in
behavior, especially during the initial few months of a course of
drug therapy, or at times of dose changes, either increases or
decreases.</span></p>
<p><a name="INV-8848d686-2170-4adb-9062-7ed36e1c7af0" id=
"INV-8848d686-2170-4adb-9062-7ed36e1c7af0"></a>The following
symptoms, anxiety, agitation, panic attacks, insomnia,
irritability, hostility, aggressiveness, impulsivity, akathisia
(psychomotor restlessness), hypomania, and mania, have been
reported in adult and pediatric patients being treated with
antidepressants for major depressive disorder as well as for other
indications, both psychiatric and nonpsychiatric. Although a causal
link between the emergence of such symptoms and either the
worsening of depression and/or the emergence of suicidal impulses
has not been established, there is concern that such symptoms may
represent precursors to emerging suicidality.</p>
<p><a name="INV-c563cc4b-71d7-49fa-ab5e-6076046d358b" id=
"INV-c563cc4b-71d7-49fa-ab5e-6076046d358b"></a>Consideration should
be given to changing the therapeutic regimen, including possibly
discontinuing the medication, in patients whose depression is
persistently worse, or who are experiencing emergent suicidality or
symptoms that might be precursors to worsening depression or
suicidality, especially if these symptoms are severe, abrupt in
onset, or were not part of the patient's presenting symptoms.</p>
<p><a name="INV-f529c7a8-5aa9-4575-b62d-ea47ea242e00" id=
"INV-f529c7a8-5aa9-4575-b62d-ea47ea242e00"></a><span class=
"Bold">Families and caregivers of patients being treated with
antidepressants for major depressive disorder or other indications,
both psychiatric and nonpsychiatric, should be alerted about the
need to monitor patients for the emergence of agitation,
irritability, unusual changes in behavior, and the other symptoms
described above, as well as the emergence of suicidality, and to
report such symptoms immediately to health care providers. Such
monitoring should include daily observation by families and
caregivers.</span> Prescriptions for nefazodone hydrochloride
tablets should be written for the smallest quantity of tablets
consistent with good patient management, in order to reduce the
risk of overdose.</p>
<p><a name="INV-9a934959-f62d-42ee-aea9-4cd5a6daf5de" id=
"INV-9a934959-f62d-42ee-aea9-4cd5a6daf5de"></a><span class=
"Bold">Screening Patients for Bipolar Disorder</span></p>
<p><a name="INV-75ffece1-5ad9-4c3a-be78-807c02b9a72b" id=
"INV-75ffece1-5ad9-4c3a-be78-807c02b9a72b"></a>A major depressive
episode may be the initial presentation of bipolar disorder. It is
generally believed (though not established in controlled trials)
that treating such an episode with an antidepressant alone may
increase the likelihood of precipitation of a mixed/manic episode
in patients at risk for bipolar disorder. Whether any of the
symptoms described above represent such a conversion is unknown.
However, prior to initiating treatment with an antidepressant,
patients with depressive symptoms should be adequately screened to
determine if they are at risk for bipolar disorder; such screening
should include a detailed psychiatric history, including a family
history of suicide, bipolar disorder, and depression. It should be
noted that nefazodone hydrochloride tablets is not approved for use
in treating bipolar depression.</p>
<p><a name="INV-a00fb5a4-04cb-43c8-a7d1-9def5a32116b" id=
"INV-a00fb5a4-04cb-43c8-a7d1-9def5a32116b"></a><span class=
"Bold">Hepatotoxicity</span></p>
<p><a name="INV-1d19504b-4307-4331-8058-231a5eb80999" id=
"INV-1d19504b-4307-4331-8058-231a5eb80999"></a>(See <span class=
"Bold">BOXED WARNING</span>.)</p>
<p><a name="INV-b4c571c2-eb02-4074-8dc8-34879ccd7556" id=
"INV-b4c571c2-eb02-4074-8dc8-34879ccd7556"></a><span class=
"Bold">Cases of life-threatening hepatic failure have been reported
in patients treated with nefazodone.</span></p>
<p><a name="INV-7b9a6ecf-3d84-49a3-8af2-f4942dfe93a7" id=
"INV-7b9a6ecf-3d84-49a3-8af2-f4942dfe93a7"></a><span class=
"Bold">The reported rate in the United States is about 1 case of
liver failure resulting in death or transplant per 250,000</span>
<span class="Bold">to 300,000 patient-years of nefazodone
treatment. This represents a rate of about 3 to 4 times the
estimated background rate of liver failure. This rate is an
underestimate because of under reporting, and the true risk could
be considerably greater than this. A large cohort study of
antidepressant users found no cases of liver failure leading to
death or transplant among nefazodone users in about 30,000
patient-years of exposure. The spontaneous report data and the
cohort study results provide estimates of the upper and lower
limits of the risk of liver failure in nefazodone-treated patients,
but are not capable of providing a precise risk
estimate.</span></p>
<p><a name="INV-853f58c0-7887-45d2-8e5b-d37c3b07e334" id=
"INV-853f58c0-7887-45d2-8e5b-d37c3b07e334"></a><span class=
"Bold">The time to liver injury for the reported liver failure
cases resulting in death or transplant generally ranged from 2
weeks to 6 months on nefazodone therapy. Although some reports
described dark urine and nonspecific prodromal symptoms (e.g.,
anorexia, malaise, and gastrointestinal symptoms), other reports
did not describe the onset of clear prodromal symptoms prior to the
onset of jaundice.</span></p>
<p><a name="INV-6c64417e-cc89-4a54-bf6b-de18fb8c0f39" id=
"INV-6c64417e-cc89-4a54-bf6b-de18fb8c0f39"></a><span class=
"Bold">The physician may consider the value of liver function
testing. Periodic serum transaminase testing has not been proven to
prevent serious injury but it is generally believed that early
detection of drug-induced hepatic injury along with immediate
withdrawal of the suspect drug enhances the likelihood for
recovery.</span></p>
<p><a name="INV-051388a6-77d5-44fd-a853-b92346b44ab0" id=
"INV-051388a6-77d5-44fd-a853-b92346b44ab0"></a><span class=
"Bold">Patients should be advised to be alert for signs and
symptoms of liver dysfunction (jaundice, anorexia, gastrointestinal
complaints, malaise, etc.) and to report them to their doctor
immediately if they occur. Ongoing clinical assessment of patients
should govern physician interventions, including diagnostic
evaluations and treatment.</span></p>
<p><a name="INV-084c37cf-b092-4e03-ae0e-758fa624bf4c" id=
"INV-084c37cf-b092-4e03-ae0e-758fa624bf4c"></a><span class=
"Bold">Nefazodone should be discontinued if clinical signs or
symptoms suggest liver failure (</span>see <span class=
"Bold">PRECAUTIONS: Information for Patients). Patients who develop
evidence of hepatocellular injury such as increased serum AST or
serum ALT levels</span> ≥ <span class="Bold">3 times the upper
limit of NORMAL, while on nefazodone should be withdrawn from the
drug. These patients should be presumed to be at increased risk for
liver injury if nefazodone is reintroduced. Accordingly, such
patients should not be considered for re-treatment.</span></p>
<p><a name="INV-b9a71be2-47af-4355-932f-51020e215315" id=
"INV-b9a71be2-47af-4355-932f-51020e215315"></a><span class=
"Bold">Potential for Interaction with Monoamine Oxidase
Inhibitors</span></p>
<p><a name="INV-8b2728b0-f522-49e7-8b8c-4b07c7904a67" id=
"INV-8b2728b0-f522-49e7-8b8c-4b07c7904a67"></a>In patients
receiving antidepressants with pharmacological properties similar
to nefazodone in combination with a monoamine oxidase inhibitor
(MAOI), there have been reports of serious, sometimes fatal,
reactions. For a selective serotonin reuptake inhibitor (SSRI),
these reactions have included hyperthermia, rigidity, myoclonus,
autonomic instability with possible rapid fluctuations of vital
signs, and mental status changes that include extreme agitation
progressing to delirium and coma. These reactions have also been
reported in patients who have recently discontinued that drug and
have been started on an MAOI. Some cases presented with features
resembling neuroleptic malignant syndrome. Severe hyperthermia and
seizures, sometimes fatal, have been reported in association with
the combined use of tricyclic antidepressants and MAOIs. These
reactions have also been reported in patients who have recently
discontinued these drugs and have been started on an MAOI.</p>
<p><a name="INV-2ace9f19-2ea7-4d6d-b3d4-27e05323eb69" id=
"INV-2ace9f19-2ea7-4d6d-b3d4-27e05323eb69"></a><span class=
"Bold">Although the effects of combined use of nefazodone and MAOI
have not been evaluated in humans or animals, because nefazodone is
an inhibitor of both serotonin and norepinephrine reuptake, it is
recommended that nefazodone not be used in combination with an
MAOI, or within 14 days of discontinuing treatment with an MAOI. At
least 1 week should be allowed after stopping nefazodone before
starting an MAOI.</span></p>
<p><a name="INV-3cbaac27-d582-4adb-93a3-8d95e3a04e6b" id=
"INV-3cbaac27-d582-4adb-93a3-8d95e3a04e6b"></a><span class=
"Bold">Interaction with Triazolobenzodiazepines</span></p>
<p><a name="INV-5a293c1f-601f-4b0e-affe-2c98e32e2a19" id=
"INV-5a293c1f-601f-4b0e-affe-2c98e32e2a19"></a>Interaction studies
of nefazodone with two triazolobenzodiazepines, i.e., triazolam and
alprazolam, metabolized by cytochrome P450 3A4, have revealed
substantial and clinically important increases in plasma
concentrations of these compounds when administered concomitantly
with nefazodone.</p>
<p><a name="INV-76cdeba1-d3e5-4db0-99e5-398592fc52d3" id=
"INV-76cdeba1-d3e5-4db0-99e5-398592fc52d3"></a><span class=
"Italics">Triazolam</span></p>
<p><a name="INV-bef89665-2f44-471f-ba3d-5c55a358aa08" id=
"INV-bef89665-2f44-471f-ba3d-5c55a358aa08"></a>When a single oral
0.25 mg dose of triazolam was coadministered with nefazodone (200
mg BID) at steady state, triazolam half-life and AUC increased
4-fold and peak concentrations increased 1.7-fold. <span class=
"Italics"><span class="Bold">Nefazodone plasma concentrations were
unaffected by triazolam</span></span>. Coadministration of
nefazodone potentiated the effects of triazolam on psychomotor
performance tests. If triazolam is coadministered with nefazodone,
a 75% reduction in the initial triazolam dosage is recommended.
Because not all commercially available dosage forms of triazolam
permit sufficient dosage reduction, coadministration of triazolam
with nefazodone should be avoided for most patients, including the
elderly. In the exceptional case where coadministration of
triazolam with nefazodone may be considered appropriate, only the
lowest possible dose of triazolam should be used (see <span class=
"Bold">CONTRAINDICATIONS</span> and <span class=
"Bold">PRECAUTIONS</span>).</p>
<p><a name="INV-782f756e-f929-4c22-a094-dc563a6c46f9" id=
"INV-782f756e-f929-4c22-a094-dc563a6c46f9"></a><span class=
"Italics">Alprazolam</span></p>
<p><a name="INV-0e48f3e2-973f-478d-920d-ad2e0b49db11" id=
"INV-0e48f3e2-973f-478d-920d-ad2e0b49db11"></a>When alprazolam (1
mg BID) and nefazodone (200 mg BID) were coadministered,
steady-state peak concentrations, AUC and half-life values for
alprazolam increased by approximately 2-fold. Nefazodone plasma
concentrations were unaffected by alprazolam. If alprazolam is
coadministered with nefazodone, a 50% reduction in the initial
alprazolam dosage is recommended. No dosage adjustment is required
for nefazodone hydrochloride.</p>
<p><a name="INV-d0a80137-713c-4a9f-ae80-5ec81320ccf3" id=
"INV-d0a80137-713c-4a9f-ae80-5ec81320ccf3"></a><span class=
"Bold">Potential Terfenadine, Astemizole, Cisapride, and Pimozide
Interactions</span></p>
<p><a name="INV-4a9cbede-d0bd-405d-a3f1-f452b4442359" id=
"INV-4a9cbede-d0bd-405d-a3f1-f452b4442359"></a><span class=
"Bold">Terfenadine, astemizole, cisapride, and pimozide are all
metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has
been demonstrated that ketoconazole, erythromycin, and other
inhibitors of CYP3A4 can block the metabolism of these drugs, which
can result in increased plasma concentrations of parent drug.
Increased plasma concentrations of terfenadine, astemizole,
cisapride, and pimozide are associated with QT prolongation and
with rare cases of serious cardiovascular adverse events, including
death, due principally to ventricular tachycardia of the torsades
de pointes type. Nefazodone has been shown in vitro to be an
inhibitor of CYP3A4. Consequently, it is recommended that
nefazodone not be used in combination with either terfenadine,
astemizole, cisapride, or pimozide (see CONTRAINDICATIONS and
PRECAUTIONS).</span></p>
<p><a name="INV-56ecd58f-3934-48a2-97b9-06197433a655" id=
"INV-56ecd58f-3934-48a2-97b9-06197433a655"></a><span class=
"Bold">Interaction with Carbamazepine</span></p>
<p><a name="INV-9312d28a-5eb7-462b-8c5a-6c13a419fbe5" id=
"INV-9312d28a-5eb7-462b-8c5a-6c13a419fbe5"></a>The coadministration
of carbamazepine 200 mg BID with nefazodone 200 mg BID, at steady
state for both drugs, resulted in almost 95% reductions in AUCs for
nefazodone and hydroxynefazodone, likely resulting in insufficient
plasma nefazodone and hydroxynefazodone concentrations for
achieving an antidepressant effect for nefazodone. Consequently, it
is recommended that nefazodone not be used in combination with
carbamazepine (see <span class="Bold">CONTRAINDICATIONS</span> and
<span class="Bold">PRECAUTIONS</span>).</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"42232-9"><a name="INV-dd20aef1-d847-4951-a185-8217916dc454" id=
"INV-dd20aef1-d847-4951-a185-8217916dc454"></a> <a name="section-9"
id="section-9"></a>
<div class="Section" data-sectioncode="42232-9"><a name=
"INV-f433c9bb-128b-4ded-aa98-516a572ea930" id=
"INV-f433c9bb-128b-4ded-aa98-516a572ea930"></a> <a name=
"section-9.1" id="section-9.1"></a>
<h2>General</h2>
<div class="Section" data-sectioncode="42232-9"><a name=
"INV-09dd4d22-25bc-4083-a3d9-5c9f2e044c74" id=
"INV-09dd4d22-25bc-4083-a3d9-5c9f2e044c74"></a> <a name=
"section-9.1.1" id="section-9.1.1"></a>
<h3><span class="Italics">Hepatotoxicity</span></h3>
<p class="First"><a name="INV-4cc5a8ca-66f1-4b5c-bfda-5ef8da09019f"
id="INV-4cc5a8ca-66f1-4b5c-bfda-5ef8da09019f"></a>(See <span class=
"Bold">BOXED WARNING.</span>)</p>
</div>
<div class="Section" data-sectioncode="42232-9"><a name=
"INV-6876b3a9-98f7-4409-a20f-7aa3f84e0bbd" id=
"INV-6876b3a9-98f7-4409-a20f-7aa3f84e0bbd"></a> <a name=
"section-9.1.2" id="section-9.1.2"></a>
<h3><span class="Italics">Postural Hypotension</span></h3>
<p class="First"><a name="INV-d7ead009-15b2-4ab2-b713-b59211795fdd"
id="INV-d7ead009-15b2-4ab2-b713-b59211795fdd"></a>A pooled analysis
of the vital signs monitored during placebo-controlled premarketing
studies revealed that 5.1% of nefazodone patients compared to 2.5%
of placebo patients (p ≤ 0.01) met criteria for a potentially
important decrease in blood pressure at some time during treatment
(systolic blood pressure ≤ 90 mmHg and a change from baseline of ≥
20 mmHg). While there was no difference in the proportion of
nefazodone and placebo patients having adverse events characterized
as ‘syncope’ (nefazodone, 0.2%; placebo, 0.3%), the rates for
adverse events characterized as ‘postural hypotension’ were as
follows: nefazodone (2.8%), tricyclic antidepressants (10.9%), SSRI
(1.1%), and placebo (0.8%). Thus, the prescriber should be aware
that there is some risk of postural hypotension in association with
nefazodone use. Nefazodone should be used with caution in patients
with known cardiovascular or cerebrovascular disease that could be
exacerbated by hypotension (history of myocardial infarction,
angina, or ischemic stroke) and conditions that would predispose
patients to hypotension (dehydration, hypovolemia, and treatment
with antihypertensive medication).</p>
</div>
<div class="Section" data-sectioncode="42232-9"><a name=
"INV-1afd7b26-547f-4218-8769-493e5f2c99bc" id=
"INV-1afd7b26-547f-4218-8769-493e5f2c99bc"></a> <a name=
"section-9.1.3" id="section-9.1.3"></a>
<h3><span class="Italics">Activation of Mania/Hypomania</span></h3>
<p class="First"><a name="INV-0bec8591-9f6f-4629-bf36-3090c91268ca"
id="INV-0bec8591-9f6f-4629-bf36-3090c91268ca"></a>During
premarketing testing, hypomania or mania occurred in 0.3% of
nefazodone-treated unipolar patients, compared to 0.3% of
tricyclic- and 0.4% of placebo-treated patients. In patients
classified as bipolar the rate of manic episodes was 1.6% for
nefazodone, 5.1% for the combined tricyclic-treated groups, and 0%
for placebo-treated patients. Activation of mania/hypomania is a
known risk in a small proportion of patients with major affective
disorder treated with other marketed antidepressants. As with all
antidepressants, nefazodone should be used cautiously in patients
with a history of mania.</p>
</div>
<div class="Section" data-sectioncode="42232-9"><a name=
"INV-c6ef862d-91b4-440e-8d13-6eecf90d33a4" id=
"INV-c6ef862d-91b4-440e-8d13-6eecf90d33a4"></a> <a name=
"section-9.1.4" id="section-9.1.4"></a>
<h3><span class="Italics">Seizures</span></h3>
<p class="First"><a name="INV-7b0b001a-d676-48fb-93b7-eea8dd5f6637"
id="INV-7b0b001a-d676-48fb-93b7-eea8dd5f6637"></a>During
premarketing testing, a recurrence of a petit mal seizure was
observed in a patient receiving nefazodone who had a history of
such seizures. In addition, one nonstudy participant reportedly
experienced a convulsion (type not documented) following a
multiple-drug overdose (see <span class="Bold">OVERDOSAGE</span>).
Rare occurrences of convulsions (including grand mal seizures)
following nefazodone administration have been reported since market
introduction. A causal relationship to nefazodone has not been
established (see <span class="Bold">ADVERSE REACTIONS</span>).</p>
</div>
<div class="Section" data-sectioncode="42232-9"><a name=
"INV-971bc28f-9025-41c9-830c-832d110d85af" id=
"INV-971bc28f-9025-41c9-830c-832d110d85af"></a> <a name=
"section-9.1.5" id="section-9.1.5"></a>
<h3><span class="Italics">Priapism</span></h3>
<p class="First"><a name="INV-62256a83-160b-4bd9-827c-a4c49d1b43a6"
id="INV-62256a83-160b-4bd9-827c-a4c49d1b43a6"></a>While priapism
did not occur during premarketing experience with nefazodone, rare
reports of priapism have been received since market introduction. A
causal relationship to nefazodone has not been established (see
<span class="Bold">ADVERSE REACTIONS</span>). If patients present
with prolonged or inappropriate erections, they should discontinue
therapy immediately and consult their physicians. If the condition
persists for more than 24 hours, an urologist should be consulted
to determine appropriate management.</p>
</div>
<div class="Section" data-sectioncode="42232-9"><a name=
"INV-4ee53e75-0901-4f25-8306-4348fac9c12c" id=
"INV-4ee53e75-0901-4f25-8306-4348fac9c12c"></a> <a name=
"section-9.1.6" id="section-9.1.6"></a>
<h3><span class="Italics">Use in Patients with Concomitant
Illness</span></h3>
<p class="First"><a name="INV-10f79987-8aad-4c80-ad81-e7bf79ce0f4c"
id="INV-10f79987-8aad-4c80-ad81-e7bf79ce0f4c"></a>Nefazodone has
not been evaluated or used to any appreciable extent in patients
with a recent history of myocardial infarction or unstable heart
disease. Patients with these diagnoses were systematically excluded
from clinical studies during the product’s premarketing testing.
Evaluation of electrocardiograms of 1153 patients who received
nefazodone in 6- to 8-week, double-blind, placebo-controlled trials
did not indicate that nefazodone is associated with the development
of clinically important ECG abnormalities. However, sinus
bradycardia, defined as heart rate ≤ 50 bpm and a decrease of at
least 15 bpm from baseline, was observed in 1.5% of
nefazodone-treated patients compared to 0.4% of placebo-treated
patients (p ≤ 0.05). Because patients with a recent history of
myocardial infarction or unstable heart disease were excluded from
clinical trials, such patients should be treated with caution.</p>
<p><a name="INV-e82b76d3-777b-46dd-907d-2049a20edc47" id=
"INV-e82b76d3-777b-46dd-907d-2049a20edc47"></a>In patients with
cirrhosis of the liver, the AUC values of nefazodone and HO-NEF
were increased by approximately 25%.</p>
</div>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-3dd9f2c3-eac4-4f17-8ddf-5aa68b0c2d70" id=
"INV-3dd9f2c3-eac4-4f17-8ddf-5aa68b0c2d70"></a> <a name=
"section-9.2" id="section-9.2"></a>
<h2><span class="Italics">Information for Patients</span></h2>
<p class="First"><a name="INV-0906dbd9-635f-4abf-a990-66046ae819d1"
id="INV-0906dbd9-635f-4abf-a990-66046ae819d1"></a><span class=
"Bold">(See Patient Information.)</span></p>
<p><a name="INV-a511a442-e24e-421f-9424-5ddd1dc2911f" id=
"INV-a511a442-e24e-421f-9424-5ddd1dc2911f"></a>Patients and their
families should be encouraged to be alert to the emergence of
anxiety, agitation, panic attacks, insomnia, irritability,
hostility, impulsivity, akathisia, hypomania, mania, worsening of
depression, and suicidal ideation, especially early during
antidepressant treatment. Such symptoms should be reported to the
patient’s physician, especially if they are severe, abrupt in
onset, or were not part of the patient’s presenting symptoms.</p>
<p><a name="INV-16445662-f48a-423b-bb8c-5473b95ed902" id=
"INV-16445662-f48a-423b-bb8c-5473b95ed902"></a>Prescribers or other
health professionals should inform patients, their families, and
their caregivers about the benefits and risks associated with
treatment with nefazodone and should counsel them in its
appropriate use. A patient Medication Guide about “Antidepressant
Medicines, Depression and other Serious Mental Illness, and
Suicidal Thoughts or Actions” is available for nefazodone. The
prescriber or health professional should instruct patients, their
families, and their caregivers to read the Medication Guide and
should assist them in understanding its contents. Patients should
be given the opportunity to discuss the contents of the Medication
Guide and to obtain answers to any questions they may have. The
complete text of the Medication Guide is reprinted at the end of
this document.</p>
<p><a name="INV-cf4c9835-e1f9-47a9-a3dd-6373c931a2cf" id=
"INV-cf4c9835-e1f9-47a9-a3dd-6373c931a2cf"></a>Patients should be
advised of the following issues and asked to alert their prescriber
if these occur while taking nefazodone.</p>
<p><a name="INV-7c516a7a-ff68-40a3-8bab-c4b60615cd9e" id=
"INV-7c516a7a-ff68-40a3-8bab-c4b60615cd9e"></a><span class=
"Bold">Clinical Worsening and Suicide Risk:</span> Patients, their
families, and their caregivers should be encouraged to be alert to
the emergence of anxiety, agitation, panic attacks, insomnia,
irritability, hostility, aggressiveness, impulsivity, akathisia
(psychomotor restlessness), hypomania, mania, other unusual changes
in behavior, worsening of depression, and suicidal ideation,
especially early during antidepressant treatment and when the dose
is adjusted up or down. Families and caregivers of patients should
be advised to look for the emergence of such symptoms on a
day-to-day basis, since changes may be abrupt. Such symptoms should
be reported to the patient's prescriber or health professional,
especially if they are severe, abrupt in onset, or were not part of
the patient's presenting symptoms. Symptoms such as these may be
associated with an increased risk for suicidal thinking and
behavior and indicate a need for very close monitoring and possibly
changes in the medication.</p>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-692620d1-e9ea-4e9e-a790-3b57d286572e" id=
"INV-692620d1-e9ea-4e9e-a790-3b57d286572e"></a> <a name=
"section-9.2.1" id="section-9.2.1"></a>
<h3><span class="Italics">Hepatotoxicity</span></h3>
<p class="First"><a name="INV-488f02c6-ea61-4dff-84fd-72dbb237565f"
id="INV-488f02c6-ea61-4dff-84fd-72dbb237565f"></a>Patients should
be informed that nefazodone therapy has been associated with liver
abnormalities ranging from asymptomatic reversible serum
transaminase increases to cases of liver failure resulting in
transplant and/or death. At present, there is no way to predict who
is likely to develop liver failure. Ordinarily, patients with
active liver disease should not be treated with nefazodone.
Patients should be advised to be alert for signs of liver
dysfunction (jaundice, anorexia, gastrointestinal complaints,
malaise, etc.) and to report them to their doctor immediately if
they occur.</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-f3360b10-ec9e-476c-adb8-f4ad62f56b42" id=
"INV-f3360b10-ec9e-476c-adb8-f4ad62f56b42"></a> <a name=
"section-9.2.2" id="section-9.2.2"></a>
<h3><span class="Italics">Time to Response/Continuation</span></h3>
<p class="First"><a name="INV-9d0fdcf9-d096-449c-94a4-fe71a569ecdc"
id="INV-9d0fdcf9-d096-449c-94a4-fe71a569ecdc"></a>As with all
antidepressants, several weeks on treatment may be required to
obtain the full antidepressant effect. Once improvement is noted,
it is important for patients to continue drug treatment as directed
by their physician.</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-e6290ad3-53e3-4858-b654-901be641b79a" id=
"INV-e6290ad3-53e3-4858-b654-901be641b79a"></a> <a name=
"section-9.2.3" id="section-9.2.3"></a>
<h3><span class="Italics">Interference With Cognitive and Motor
Performance</span></h3>
<p class="First"><a name="INV-f41f0c87-3cc0-4d50-aadb-833d78fa1f4f"
id="INV-f41f0c87-3cc0-4d50-aadb-833d78fa1f4f"></a>Since any
psychoactive drug may impair judgment, thinking, or motor skills,
patients should be cautioned about operating hazardous machinery,
including automobiles, until they are reasonably certain that
nefazodone therapy does not adversely affect their ability to
engage in such activities.</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-da144490-5196-43c4-b2fd-4840df39b587" id=
"INV-da144490-5196-43c4-b2fd-4840df39b587"></a> <a name=
"section-9.2.4" id="section-9.2.4"></a>
<h3><span class="Italics">Pregnancy</span></h3>
<p class="First"><a name="INV-6c968ad4-38ab-49a1-a60e-c4db6219c545"
id="INV-6c968ad4-38ab-49a1-a60e-c4db6219c545"></a>Patients should
be advised to notify their physician if they become pregnant or
intend to become pregnant during therapy.</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-7767afe5-b029-43fa-b9af-4a91562260f7" id=
"INV-7767afe5-b029-43fa-b9af-4a91562260f7"></a> <a name=
"section-9.2.5" id="section-9.2.5"></a>
<h3><span class="Italics">Nursing</span></h3>
<p class="First"><a name="INV-c99c53de-7f67-488f-af1a-b5de229d5e46"
id="INV-c99c53de-7f67-488f-af1a-b5de229d5e46"></a>Patients should
be advised to notify their physician if they are breast-feeding an
infant (see <span class="Bold">PRECAUTIONS, Nursing
Mothers</span>).</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-ed906834-9ab9-47a8-94b1-7d481d3967ce" id=
"INV-ed906834-9ab9-47a8-94b1-7d481d3967ce"></a> <a name=
"section-9.2.6" id="section-9.2.6"></a>
<h3><span class="Italics">Concomitant Medication</span></h3>
<p class="First"><a name="INV-3022fd70-d498-4a07-8428-202aadcf8f86"
id="INV-3022fd70-d498-4a07-8428-202aadcf8f86"></a>Patients should
be advised to inform their physicians if they are taking, or plan
to take, any prescription or over-the-counter drugs, since there is
a potential for interactions. Significant caution is indicated if
nefazodone is to be used in combination with XANAX <span class=
"Sup">®</span><span class="Sup">1</span> (alprazolam), concomitant
use with HALCION<span class="Sup">®1</span> (triazolam), should be
avoided for most patients including the elderly, and concomitant
use with SELDANE<span class="Sup">®2</span> (terfenadine),
HISMANAL<span class="Sup">®3</span> (astemizole),
PROPULSID<span class="Sup">®3</span> (cisapride), ORAP<span class=
"Sup">®4</span> (pimozide), or TEGRETOL<span class=
"Sup">®</span><span class="Sup">5</span> (carbamazepine), is
contraindicated (see <span class="Bold">CONTRAINDICATIONS</span>
and <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-f672c1dd-1276-4e5a-aaa9-d84eef577125" id=
"INV-f672c1dd-1276-4e5a-aaa9-d84eef577125"></a> <a name=
"section-9.2.7" id="section-9.2.7"></a>
<h3><span class="Italics">Alcohol</span></h3>
<p class="First"><a name="INV-4d738dab-6544-477e-898a-125350502b31"
id="INV-4d738dab-6544-477e-898a-125350502b31"></a>Patients should
be advised to avoid alcohol while taking nefazodone.</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-08fd0b65-91b6-42be-966b-dc76316f934a" id=
"INV-08fd0b65-91b6-42be-966b-dc76316f934a"></a> <a name=
"section-9.2.8" id="section-9.2.8"></a>
<h3><span class="Italics">Allergic Reactions</span></h3>
<p class="First"><a name="INV-c41ad9be-61e3-4ad8-aea8-f8a395560f0d"
id="INV-c41ad9be-61e3-4ad8-aea8-f8a395560f0d"></a>Patients should
be advised to notify their physician if they develop a rash, hives,
or a related allergic phenomenon.</p>
</div>
<div class="Section" data-sectioncode="34076-0"><a name=
"INV-3dc87f40-d828-4960-9d35-a80313ea26c9" id=
"INV-3dc87f40-d828-4960-9d35-a80313ea26c9"></a> <a name=
"section-9.2.9" id="section-9.2.9"></a>
<h3><span class="Italics">Visual Disturbances</span></h3>
<p class="First"><a name="INV-8eed39f6-b9de-4317-8da1-01babeeb4bb9"
id="INV-8eed39f6-b9de-4317-8da1-01babeeb4bb9"></a>There have been
reports of visual disturbances associated with the use of
nefazodone, including blurred vision, scotoma, and visual trails.
Patients should be advised to notify their physician if they
develop visual disturbances. (See <span class="Bold">ADVERSE
REACTIONS</span>.)</p>
</div>
</div>
<div class="Section" data-sectioncode="34075-2"><a name=
"INV-6e03c9e2-1c32-4ea6-a59b-1220ed92696e" id=
"INV-6e03c9e2-1c32-4ea6-a59b-1220ed92696e"></a> <a name=
"section-9.3" id="section-9.3"></a>
<h2>Laboratory Tests</h2>
<p class="First"><a name="INV-9b26e6b4-327e-467b-8f7f-4f5da686b332"
id="INV-9b26e6b4-327e-467b-8f7f-4f5da686b332"></a>There are no
specific laboratory tests recommended.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-9288b3dd-17ed-44e8-9298-e24ae7ce53a4" id=
"INV-9288b3dd-17ed-44e8-9298-e24ae7ce53a4"></a> <a name=
"section-9.4" id="section-9.4"></a>
<h2>Drug Interactions</h2>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-9a41f732-5e4f-4195-933b-d6f2d355174c" id=
"INV-9a41f732-5e4f-4195-933b-d6f2d355174c"></a> <a name=
"section-9.4.1" id="section-9.4.1"></a>
<h3>Drugs Highly Bound to Plasma Protein</h3>
<p class="First"><a name="INV-eefa8e1f-ff39-4673-a36f-71912f613a5f"
id="INV-eefa8e1f-ff39-4673-a36f-71912f613a5f"></a>Because
nefazodone is highly bound to plasma protein (see <span class=
"Bold">CLINICAL PHARMACOLOGY, Pharmacokinetics</span>),
administration of nefazodone to a patient taking another drug that
is highly protein bound may cause increased free concentrations of
the other drug, potentially resulting in adverse events.
Conversely, adverse effects could result from displacement of
nefazodone by other highly bound drugs.</p>
<p><a name="INV-2a3ff933-d447-495f-b676-e86dd81fe8fc" id=
"INV-2a3ff933-d447-495f-b676-e86dd81fe8fc"></a>Warfarin—There were
no effects on the prothrombin or bleeding times or upon the
pharmacokinetics of R-warfarin when nefazodone (200 mg BID) was
administered for 1 week to subjects who had been pretreated for 2
weeks with warfarin. Although the coadministration of nefazodone
did decrease the subjects’ exposure to S-warfarin by 12%, the lack
of effects on the prothrombin and bleeding times indicates this
modest change is not clinically significant. Although these results
suggest no adjustments in warfarin dosage are required when
nefazodone is administered to patients stabilized on warfarin, such
patients should be monitored as required by standard medical
practices.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-82b4fb4b-1ccf-4f1c-b656-69e6a06dbc43" id=
"INV-82b4fb4b-1ccf-4f1c-b656-69e6a06dbc43"></a> <a name=
"section-9.4.2" id="section-9.4.2"></a>
<h3><span class="Italics">CNS-Active Drugs</span></h3>
<p class="First"><a name="INV-f612b537-259b-45d4-9254-365590eeb538"
id="INV-f612b537-259b-45d4-9254-365590eeb538"></a>Monoamine Oxidase
Inhibitors—See <span class="Bold">WARNINGS</span>.</p>
<p><a name="INV-b16c6252-56af-4d66-af41-07034112ee56" id=
"INV-b16c6252-56af-4d66-af41-07034112ee56"></a>Haloperidol—When a
single oral 5 mg dose of haloperidol was coadministered with
nefazodone (200 mg ID) at steady state, haloperidol apparent
clearance decreased by 35% with no significant increase in peak
haloperidol plasma concentrations or time of peak. This change is
of unknown clinical significance. Pharmacodynamic effects of
haloperidol were generally not altered significantly. There were no
changes in the pharmacokinetic parameters for nefazodone. Dosage
adjustment of haloperidol may be necessary when coadministered with
nefazodone.</p>
<p><a name="INV-3651b46d-6704-428c-832d-eab88aabd688" id=
"INV-3651b46d-6704-428c-832d-eab88aabd688"></a>Lorazepam—When
lorazepam (2 mg BID) and nefazodone (200 mg BID) were
coadministered to steady state, there was no change in any
pharmacokinetic parameter for either drug compared to each drug
administered alone. Therefore, dosage adjustment is not necessary
for either drug when coadministered.</p>
<p><a name="INV-66733ec8-aca9-4a23-b682-839b96a1b4c4" id=
"INV-66733ec8-aca9-4a23-b682-839b96a1b4c4"></a>Triazolam/Alprazolam—See
<span class="Bold">CONTRAINDICATIONS</span> and <span class=
"Bold">WARNINGS</span>.</p>
<p><a name="INV-1f200493-d35c-4ecb-8486-efd643bed595" id=
"INV-1f200493-d35c-4ecb-8486-efd643bed595"></a>Alcohol—Although
nefazodone did not potentiate the cognitive and psychomotor effects
of alcohol in experiments with normal subjects, the concomitant use
of nefazodone and alcohol in depressed patients is not advised.</p>
<p><a name="INV-13166d34-8317-49ff-a910-35d0c80386bf" id=
"INV-13166d34-8317-49ff-a910-35d0c80386bf"></a>Buspirone—In a study
of steady-state pharmacokinetics in healthy volunteers,
coadministration of buspirone (2.5 or 5 mg BID) with nefazodone
(250 mg BID) resulted in marked increases in plasma buspirone
concentrations (increases up to 20-fold in C <span class=
"Sub">max</span> and up to 50-fold in AUC) and statistically
significant decreases (about 50%) in plasma concentrations of the
buspirone metabolite 1-pyrimidinylpiperazine. With 5mg BID doses of
buspirone, slight increases in AUC were observed for nefazodone
(23%) and its metabolites hydroxynefazodone (17%) and mCPP (9%).
Subjects receiving nefazodone 250 mg BID and buspirone 5 mg BID
experienced lightheadedness, asthenia, dizziness, and somnolence,
adverse events also observed with either drug alone. If the two
drugs are to be used in combination, a low dose of buspirone (e.g.,
2.5 mg QD.) is recommended. Subsequent dose adjustment of either
drug should be based on clinical assessment.</p>
<p><a name="INV-83ccfe68-5d8e-4a58-8f0c-dd5d3466c0bf" id=
"INV-83ccfe68-5d8e-4a58-8f0c-dd5d3466c0bf"></a>Pimozide—See
<span class="Bold">CONTRAINDICATIONS, WARNINGS,</span> and
<span class="Bold">PRECAUTIONS</span>: <span class=
"Italics">Pharmacokinetics of Nefazodone in</span> “<span class=
"Italics">Poor Metabolizers” and Potential Interaction with Drugs
that Inhibit and/or Are Metabolized by Cytochrome P450
Isozymes</span>.</p>
<p><a name="INV-673ee8d4-94bc-4400-93b2-58ccb5e0b6af" id=
"INV-673ee8d4-94bc-4400-93b2-58ccb5e0b6af"></a>Fluoxetine—When
fluoxetine (20 mg QD) and nefazodone (200 mg BID) were administered
at steady state there were no changes in the pharmacokinetic
parameters for fluoxetine or its metabolite, norfluoxetine.
Similarly, there were no changes in the pharmacokinetic parameters
of nefazodone or HO-NEF; however, the mean AUC levels of the
nefazodone metabolites mCPP and triazole-dione increased by 3- to
6-fold and 1.3-fold, respectively. When a 200 mg dose of nefazodone
was administered to subjects who had been receiving fluoxetine for
1 week, there was an increased incidence of transient adverse
events such as headache, lightheadedness, nausea, or paresthesia,
possibly due to the elevated mCPP levels. Patients who are switched
from fluoxetine to nefazodone without an adequate washout period
may experience similar transient adverse events. The possibility of
this happening can be minimized by allowing a washout period before
initiating nefazodone therapy and by reducing the initial dose of
nefazodone. Because of the long half-life of fluoxetine and its
metabolites, this washout period may range from one to several
weeks depending on the dose of fluoxetine and other individual
patient variables.</p>
<p><a name="INV-2eb1e097-f8bf-42ec-9b65-33a00cc6f6f2" id=
"INV-2eb1e097-f8bf-42ec-9b65-33a00cc6f6f2"></a>Phenytoin—Pretreatment
for 7 days with 200 mg BID of nefazodone had no effect on the
pharmacokinetics of a single 300 mg oral dose of phenytoin.
However, due to the nonlinear pharmacokinetics of phenytoin, the
failure to observe a significant effect on the single-dose
pharmacokinetics of phenytoin does not preclude the possibility of
a clinically significant interaction with nefazodone when phenytoin
is dosed chronically. However, no change in the initial dosage of
phenytoin is considered necessary and any subsequent adjustment of
phenytoin dosage should be guided by usual clinical practices.</p>
<p><a name="INV-308b691b-bcd4-4d31-864e-6758195882c9" id=
"INV-308b691b-bcd4-4d31-864e-6758195882c9"></a>Desipramine—When
nefazodone (150 mg BID) and desipramine (75 mg QD) were
administered together there were no changes in the pharmacokinetics
of desipramine or its metabolite, 2-hydroxy desipramine. There were
also no changes in the pharmacokinetics of nefazodone or its
triazole-dione metabolite, but the AUC and C <span class=
"Sub">max</span> of mCPP increased by 44% and 48%, respectively,
while the AUC of HO-NEF decreased by 19%. No changes in doses of
either nefazodone or desipramine are necessary when the two drugs
are given concomitantly. Subsequent dose adjustments should be made
on the basis of clinical response.</p>
<p><a name="INV-dd5865dd-261f-4ce1-8e8b-b46d765efce5" id=
"INV-dd5865dd-261f-4ce1-8e8b-b46d765efce5"></a>Lithium—In 13
healthy subjects the coadministration of nefazodone (200 mg BID)
with lithium (500 mg BID) for 5 days (steady-state conditions) was
found to be well tolerated. When the two drugs were coadministered,
there were no changes in the steady-state pharmacokinetics of
either lithium, nefazodone, or its metabolite HO-NEF; however,
there were small decreases in the steady-state plasma
concentrations of two nefazodone metabolites, mCPP and
triazole-dione, which are considered not to be of clinical
significance. Therefore, no dosage adjustment of either lithium or
nefazodone is required when they are coadministered.</p>
<p><a name="INV-7975a6f4-1167-4dd3-9156-3b6fd2cfceb4" id=
"INV-7975a6f4-1167-4dd3-9156-3b6fd2cfceb4"></a>Carbamazepine—The
coadministration of nefazodone (200 mg BID) for 5 days to 12
healthy subjects on carbamazepine who had achieved steady state
(200 mg BID) was found to be well tolerated. Steady-state
conditions for carbamazepine, nefazodone, and several of their
metabolites were achieved by day 5 of coadministration. With
coadministration of the two drugs there were significant increases
in the steady-state C <span class="Sub">max</span> and AUC of
carbamazepine (23% and 23%, respectively), while the steady-state
C<span class="Sub">max</span> and the AUC of the carbamazepine
metabolite, 10,11 epoxycarbamazepine, decreased by 21% and 20%,
respectively. The coadministration of the two drugs significantly
reduced the steady-state C<span class="Sub">max</span> and AUC of
nefazodone by 86% and 93%, respectively. Similar reductions in the
C<span class="Sub">max</span> and AUC of HO-NEF were also observed
(85% and 94%), while the reductions in C<span class=
"Sub">max</span> and AUC of mCPP and triazole-dione were more
modest (13% and 44% for the former and 28% and 57% for the latter).
Due to the potential for coadministration of carbamazepine to
result in insufficient plasma nefazodone and hydroxynefazodone
concentrations for achieving an antidepressant effect for
nefazodone, it is recommended that nefazodone not be used in
combination with carbamazepine (see <span class=
"Bold">CONTRAINDICATIONS</span> and <span class=
"Bold">WARNINGS</span>).</p>
<p><a name="INV-4980ddef-7dc5-426a-8ddd-589c08c12999" id=
"INV-4980ddef-7dc5-426a-8ddd-589c08c12999"></a>General
Anesthetics—Little is known about the potential for interaction
between nefazodone and general anesthetics; therefore, prior to
elective surgery, nefazodone should be discontinued for as long as
clinically feasible.</p>
<p><a name="INV-7868c36f-520b-444f-9f2f-06e176296157" id=
"INV-7868c36f-520b-444f-9f2f-06e176296157"></a>Other CNS-Active
Drugs—The use of nefazodone in combination with other CNS-active
drugs has not been systematically evaluated. Consequently, caution
is advised if concomitant administration of nefazodone
hydrochloride and such drugs is required.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-ff3c66fc-9c93-4042-b602-bfe24387069b" id=
"INV-ff3c66fc-9c93-4042-b602-bfe24387069b"></a> <a name=
"section-9.4.3" id="section-9.4.3"></a>
<h3><span class="Italics">Cimetidine</span></h3>
<p class="First"><a name="INV-47d650ed-897d-4804-bf83-5a6f5b3692e8"
id="INV-47d650ed-897d-4804-bf83-5a6f5b3692e8"></a>When nefazodone
(200 mg BID) and cimetidine (300 mg QID) were coadministered for
one week, no change in the steady-state pharmacokinetics of either
nefazodone or cimetidine was observed compared to each dosed alone.
Therefore, dosage adjustment is not necessary for either drug when
coadministered.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-80a775b0-4884-43e5-9a84-095b8f55e177" id=
"INV-80a775b0-4884-43e5-9a84-095b8f55e177"></a> <a name=
"section-9.4.4" id="section-9.4.4"></a>
<h3>Theophylline</h3>
<p class="First"><a name="INV-2bab1a85-e018-402e-9937-871a314a00e6"
id="INV-2bab1a85-e018-402e-9937-871a314a00e6"></a>When nefazodone
(200 mg BID) was given to patients being treated with theophylline
(600 to 1200 mg/day) for chronic obstructive pulmonary disease,
there was no change in the steady-state pharmacokinetics of either
nefazodone or theophylline. FEV1 measurements taken when
theophylline and nefazodone were coadministered did not differ from
baseline dosage (i.e., when theophylline was administered alone).
Therefore, dosage adjustment is not necessary for either drug when
coadministered.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-9f63239f-27cf-44d0-9329-a6b2ac428c9b" id=
"INV-9f63239f-27cf-44d0-9329-a6b2ac428c9b"></a> <a name=
"section-9.4.5" id="section-9.4.5"></a>
<h3><span class="Italics">Cardiovascular-Active Drugs</span></h3>
<p class="First"><a name="INV-c7247331-000d-499f-9d01-787813f8dcb0"
id="INV-c7247331-000d-499f-9d01-787813f8dcb0"></a>Digoxin—When
nefazodone (200 mg BID) and digoxin (0.2 mg QD) were coadministered
for 9 days to healthy male volunteers (n = 18) who were phenotyped
as CYP2D6 extensive metabolizers, C <span class="Sub">max</span>,
C<span class="Sub">min</span>, and AUC of digoxin were increased by
29%, 27%, and 15%, respectively. Digoxin had no effects on the
pharmacokinetics of nefazodone and its active metabolites. Because
of the narrow therapeutic index of digoxin, caution should be
exercised when nefazodone and digoxin are coadministered; plasma
level monitoring for digoxin is recommended.</p>
<p><a name="INV-ba3b93d8-b162-4a22-9a44-8e403e621adf" id=
"INV-ba3b93d8-b162-4a22-9a44-8e403e621adf"></a>Propranolol—The
coadministration of nefazodone (200 mg BID) and propranolol (40 mg
BID) for 5.5 days to healthy male volunteers (n = 18), including 3
poor and 15 extensive CYP2D6 metabolizers, resulted in 30% and 14%
reductions in C <span class="Sub">max</span> and AUC of
propranolol, respectively, and a 14% reduction in C<span class=
"Sub">max</span> for the metabolite, 4-hydroxypropranolol. The
kinetics of nefazodone, hydroxynefazodone, and triazole-dione were
not affected by coadministration of propranolol. However,
C<span class="Sub">max</span>, C<span class="Sub">min</span>, and
AUC of m-chlorophenylpiperazine were increased by 23%, 54%, and
28%, respectively. No change in initial dose of either drug is
necessary and dose adjustments should be made on the basis of
clinical response.</p>
<p><a name="INV-f99dce98-5d5e-4eea-9a7e-1d2d6765036b" id=
"INV-f99dce98-5d5e-4eea-9a7e-1d2d6765036b"></a>HMG-CoA Reductase
Inhibitors—When single 40 mg doses of simvastatin or atorvastatin,
both substrates of CYP3A4, were given to healthy adult volunteers
who had received nefazodone 200 mg BID for 6 days, approximately
20-fold increases in plasma concentrations of simvastatin and
simvastatin acid and 3- to 4- fold increases in plasma
concentrations of atorvastatin and atorvastatin lactone were seen.
These effects appear to be due to the inhibition of CYP3A4 by
nefazodone because, in the same study, nefazodone had no
significant effect on the plasma concentrations of pravastatin,
which is not metabolized by CYP3A4 to a clinically significant
extent.</p>
<p><a name="INV-ca735e09-7355-4fa4-a1c4-cddd9329c238" id=
"INV-ca735e09-7355-4fa4-a1c4-cddd9329c238"></a>There have been rare
reports of rhabdomyolysis involving patients receiving the
combination of nefazodone and either simvastatin or lovastatin,
also a substrate of CYP3A4 (see <span class="Bold">ADVERSE
REACTIONS: Postintroduction Clinical Experience</span>).
Rhabdomyolysis has been observed in patients receiving HMG-CoA
reductase inhibitors administered alone (at recommended dosages)
and in particular, for certain drugs in this class, when given in
combination with inhibitors of the CYP3A4 isozyme.</p>
<p><a name="INV-5e42d0b5-8515-4e05-8881-69e51778d046" id=
"INV-5e42d0b5-8515-4e05-8881-69e51778d046"></a>Caution should be
used if nefazodone is administered in combination with HMG-CoA
reductase inhibitors that are metabolized by CYP3A4, such as
simvastatin, atorvastatin, and lovastatin, and dosage adjustments
of these HMG-CoA reductase inhibitors are recommended. Since
metabolic interactions are unlikely between nefazodone and HMG-CoA
reductase inhibitors that undergo little or no metabolism by the
CYP3A4 isozyme, such as pravastatin or fluvastatin, dosage
adjustments should not be necessary.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-48295a33-b981-4f49-900b-d2ab1a87141b" id=
"INV-48295a33-b981-4f49-900b-d2ab1a87141b"></a> <a name=
"section-9.4.6" id="section-9.4.6"></a>
<h3><span class="Italics">Immunosuppressive Agents</span></h3>
<p class="First"><a name="INV-a7f90678-8867-4f7a-9788-f72198492195"
id="INV-a7f90678-8867-4f7a-9788-f72198492195"></a>There have been
reports of increased blood concentrations of cyclosporine and
tacrolimus into toxic ranges when patients received these drugs
concomitantly with nefazodone. Both cyclosporine and tacrolimus are
substrates of CYP3A4, and nefazodone is known to inhibit this
enzyme. If either cyclosporine or tacrolimus is administered with
nefazodone, blood concentrations of the immunosuppressive agent
should be monitored and dosage adjusted accordingly.</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-7dbafbac-2bb0-4f59-b059-2fb2c83f7248" id=
"INV-7dbafbac-2bb0-4f59-b059-2fb2c83f7248"></a> <a name=
"section-9.4.7" id="section-9.4.7"></a>
<h3><span class="Italics">Pharmacokinetics of Nefazodone in ‘Poor
Metabolizers’ and Potential Interaction with Drugs that Inhibit
and/or Are Metabolized by Cytochrome P450 Isozymes</span></h3>
<p class="First"><a name="INV-685ed751-84f1-4196-a5a5-1b0e3d308ed7"
id="INV-685ed751-84f1-4196-a5a5-1b0e3d308ed7"></a>CYP3A4
Isozyme—Nefazodone has been shown <span class="Italics">in
vitro</span> to be an inhibitor of CYP3A4. This is consistent with
the interactions observed between nefazodone and triazolam,
alprazolam, buspirone, atorvastatin, and simvastatin, drugs
metabolized by this isozyme. Consequently, caution is indicated in
the combined use of nefazodone with any drugs known to be
metabolized by CYP3A4. In particular, the combined use of
nefazodone with triazolam should be avoided for most patients,
including the elderly. The combined use of nefazodone with
terfenadine, astemizole, cisapride, or pimozide is contraindicated
(see <span class="Bold">CONTRAINDICATIONS</span> and <span class=
"Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"INV-63b0c155-a40d-4087-8d6d-f1e1365d36f6" id=
"INV-63b0c155-a40d-4087-8d6d-f1e1365d36f6"></a> <a name=
"section-9.4.8" id="section-9.4.8"></a>
<h3><span class="Italics">Electroconvulsive Therapy</span>
(ECT)</h3>
<p class="First"><a name="INV-147af6cc-a05e-4fb9-a62b-c6356dbfc78a"
id="INV-147af6cc-a05e-4fb9-a62b-c6356dbfc78a"></a>There are no
clinical studies of the combined use of ECT and nefazodone.</p>
</div>
</div>
<div class="Section" data-sectioncode="34083-6"><a name=
"INV-bb15a43e-7d60-4244-9623-b63784f02121" id=
"INV-bb15a43e-7d60-4244-9623-b63784f02121"></a> <a name=
"section-9.5" id="section-9.5"></a>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectioncode="34083-6"><a name=
"INV-6e606175-4a08-4927-85c8-7724ae9bda24" id=
"INV-6e606175-4a08-4927-85c8-7724ae9bda24"></a> <a name=
"section-9.5.1" id="section-9.5.1"></a>
<h3><span class="Italics">Carcinogenesis</span></h3>
<p class="First"><a name="INV-e8c72d57-0df7-4c37-b810-de7b937225eb"
id="INV-e8c72d57-0df7-4c37-b810-de7b937225eb"></a>There is no
evidence of carcinogenicity with nefazodone. The dietary
administration of nefazodone to rats and mice for 2 years at daily
doses of up to 200 mg/kg and 800 mg/kg, respectively, which are
approximately 3 and 6 times, respectively, the maximum human daily
dose on a mg/m <span class="Sup">2</span> basis, produced no
increase in tumors.</p>
</div>
<div class="Section" data-sectioncode="34083-6"><a name=
"INV-cd6a9a90-d4bf-4967-b3ba-23721b40f2be" id=
"INV-cd6a9a90-d4bf-4967-b3ba-23721b40f2be"></a> <a name=
"section-9.5.2" id="section-9.5.2"></a>
<h3><span class="Italics">Mutagenesis</span></h3>
<p class="First"><a name="INV-7c8315d6-d582-42c9-a939-1c627074020b"
id="INV-7c8315d6-d582-42c9-a939-1c627074020b"></a>Nefazodone has
been shown to have no genotoxic effects based on the following
assays: bacterial mutation assays, a DNA repair assay in cultured
rat hepatocytes, a mammalian mutation assay in Chinese hamster
ovary cells, an <span class="Italics">in vivo</span> cytogenetics
assay in rat bone marrow cells, and a rat dominant lethal
study.</p>
</div>
<div class="Section" data-sectioncode="34083-6"><a name=
"INV-f3f95540-4ebe-4429-9879-aebede70b1fc" id=
"INV-f3f95540-4ebe-4429-9879-aebede70b1fc"></a> <a name=
"section-9.5.3" id="section-9.5.3"></a>
<h3><span class="Italics">Impairment of Fertility</span></h3>
<p class="First"><a name="INV-70414579-e166-442b-918d-eedb9a75add7"
id="INV-70414579-e166-442b-918d-eedb9a75add7"></a>A fertility study
in rats showed a slight decrease in fertility at 200 mg/kg/day
(approximately three times the maximum human daily dose on a mg/m
<span class="Sup">2</span> basis) but not at 100 mg/kg/day
(approximately 1.5 times the maximum human daily dose on a
mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectioncode="42228-7"><a name=
"INV-cda68f4e-1299-4940-9361-1f9db6a3d65e" id=
"INV-cda68f4e-1299-4940-9361-1f9db6a3d65e"></a> <a name=
"section-9.6" id="section-9.6"></a>
<h2>Pregnancy</h2>
<div class="Section" data-sectioncode="42228-7"><a name=
"INV-d02cf7ad-01ba-41b5-990a-4641e18ca789" id=
"INV-d02cf7ad-01ba-41b5-990a-4641e18ca789"></a> <a name=
"section-9.6.1" id="section-9.6.1"></a>
<h3><span class="Italics">Teratogenic Effects—Pregnancy Category
C</span></h3>
<p class="First"><a name="INV-9539aebf-4b01-4a58-93d1-a9182af6b2a6"
id="INV-9539aebf-4b01-4a58-93d1-a9182af6b2a6"></a>Reproduction
studies have been performed in pregnant rabbits and rats at daily
doses up to 200 and 300 mg/kg, respectively (approximately 6 and 5
times, respectively, the maximum human daily dose on a mg/m
<span class="Sup">2</span> basis). No malformations were observed
in the offspring as a result of nefazodone treatment. However,
increased early pup mortality was seen in rats at a dose
approximately five times the maximum human dose, and decreased pup
weights were seen at this and lower doses, when dosing began during
pregnancy and continued until weaning. The cause of these deaths is
not known. The no-effect dose for rat pup mortality was 1 to 3
times the human dose on a mg/m<span class="Sup">2</span> basis.
There are no adequate and well-controlled studies in pregnant
women. Nefazodone should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectioncode="34079-4"><a name=
"INV-6cef6aaf-9fe3-4fda-bb1b-273b2b6ead50" id=
"INV-6cef6aaf-9fe3-4fda-bb1b-273b2b6ead50"></a> <a name=
"section-9.7" id="section-9.7"></a>
<h2>Labor and Delivery</h2>
<p class="First"><a name="INV-ceaa93f7-e4dc-4d42-9674-595b46264174"
id="INV-ceaa93f7-e4dc-4d42-9674-595b46264174"></a>The effect of
nefazodone hydrochloride on labor and delivery in humans is
unknown.</p>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"INV-4c57280a-e83e-4a3d-b86a-ab37975c0199" id=
"INV-4c57280a-e83e-4a3d-b86a-ab37975c0199"></a> <a name=
"section-9.8" id="section-9.8"></a>
<h2>Nursing Mothers</h2>
<p class="First"><a name="INV-1616bc71-bf4d-4e5b-b32b-24828c9510cf"
id="INV-1616bc71-bf4d-4e5b-b32b-24828c9510cf"></a>It is not known
whether nefazodone or its metabolites are excreted in human milk.
Because many drugs are excreted in human milk, caution should be
exercised when nefazodone is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"INV-e69a2af8-3558-4f98-a464-7ca8e8fb231a" id=
"INV-e69a2af8-3558-4f98-a464-7ca8e8fb231a"></a> <a name=
"section-9.9" id="section-9.9"></a>
<h2>Pediatric Use</h2>
<p class="First"><a name="INV-b63b92d3-799d-4ef2-b0e5-433b041fa460"
id="INV-b63b92d3-799d-4ef2-b0e5-433b041fa460"></a>Safety and
effectiveness in individuals below 18 years of age have not been
established (see <span class="Bold">WARNINGS-Clinical Worsening and
Suicide Risk</span>). Two placebo-controlled trials in 286
pediatric patients with MDD have been conducted with nefazodone,
and the data were not sufficient to support a claim for use in
pediatric patients. Anyone considering the use of nefazodone
hydrochloride tablets in a child or adolescent must balance the
potential risks with the clinical need.</p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name=
"INV-d03706e6-b6da-452d-8b54-63945f945c76" id=
"INV-d03706e6-b6da-452d-8b54-63945f945c76"></a> <a name=
"section-9.10" id="section-9.10"></a>
<h2>Geriatric Use</h2>
<p class="First"><a name="INV-c39eef22-1510-4671-bc18-7b4e62e1c27c"
id="INV-c39eef22-1510-4671-bc18-7b4e62e1c27c"></a>Of the
approximately 7000 patients in clinical studies who received
nefazodone for the treatment of depression, 18% were 65 years and
older, while 5% were 75 years and older. Based on monitoring of
adverse events, vital signs, electrocardiograms, and results of
laboratory tests, no overall differences in safety between elderly
and younger patients were observed in clinical studies. Efficacy in
the elderly has not been demonstrated in placebo-controlled trials.
Other reported clinical experience has not identified differences
in responses between elderly and younger patients, but greater
sensitivity of some older individuals cannot be ruled out.</p>
<p><a name="INV-96482912-75fb-4463-93cb-8490633caafd" id=
"INV-96482912-75fb-4463-93cb-8490633caafd"></a>Due to the increased
systemic exposure to nefazodone seen in single-dose studies in
elderly patients (see <span class="Bold">CLINICAL PHARMACOLOGY,
Pharmacokinetics</span>), treatment should be initiated at half the
usual dose, but titration upward should take place over the same
range as in younger patients (see <span class="Bold">DOSAGE AND
ADMINISTRATION</span>). The usual precautions should be observed in
elderly patients who have concomitant medical illnesses or who are
receiving concomitant drugs.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="INV-18d8ab54-1bb2-4635-8503-d53ca9e78cdb" id=
"INV-18d8ab54-1bb2-4635-8503-d53ca9e78cdb"></a> <a name=
"section-10" id="section-10"></a>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-84e51c1f-c5cf-42e6-a653-870841abed24" id=
"INV-84e51c1f-c5cf-42e6-a653-870841abed24"></a> <a name=
"section-10.1" id="section-10.1"></a>
<h2>Associated with Discontinuation of Treatment</h2>
<p class="First"><a name="INV-42477143-9eb4-4d74-bda2-380283987a5c"
id="INV-42477143-9eb4-4d74-bda2-380283987a5c"></a>Approximately 16%
of the 3496 patients who received nefazodone hydrochloride in
worldwide premarketing clinical trials discontinued treatment due
to an adverse experience. The more common (≥ 1%) events in clinical
trials associated with discontinuation and considered to be drug
related (i.e., those events associated with dropout at a rate
approximately twice or greater for nefazodone compared to placebo)
included: nausea (3.5%), dizziness (1.9%), insomnia (1.5%),
asthenia (1.3%), and agitation (1.2%).</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-fb8ccf71-7740-4a79-bf0b-dc3232fc5db9" id=
"INV-fb8ccf71-7740-4a79-bf0b-dc3232fc5db9"></a> <a name=
"section-10.2" id="section-10.2"></a>
<h2>Incidence in Controlled Trials</h2>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-47fc90d1-4b09-446b-af2f-5f82a3b6f45d" id=
"INV-47fc90d1-4b09-446b-af2f-5f82a3b6f45d"></a> <a name=
"section-10.2.1" id="section-10.2.1"></a>
<h3><span class="Italics">Commonly Observed Adverse Events in
Controlled Clinical Trials</span></h3>
<p class="First"><a name="INV-ce15bba4-8920-466e-a33d-2f49841a8314"
id="INV-ce15bba4-8920-466e-a33d-2f49841a8314"></a>The most commonly
observed adverse events associated with the use of nefazodone
(incidence of 5% or greater) and not seen at an equivalent
incidence among placebo-treated patients (i.e., significantly
higher incidence for nefazodone compared to placebo, p ≤ 0.05),
derived from the table below, were: somnolence, dry mouth, nausea,
dizziness, constipation, asthenia, lightheadedness, blurred vision,
confusion, and abnormal vision.</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-90b5c368-5275-4d98-8a50-eaaa108bbe69" id=
"INV-90b5c368-5275-4d98-8a50-eaaa108bbe69"></a> <a name=
"section-10.2.2" id="section-10.2.2"></a>
<h3><span class="Italics">Adverse Events Occurring at an Incidence
of 1% or More Among Nefazodone-Treated Patients</span></h3>
<p class="First"><a name="INV-dc23b25d-4aa8-4a61-b9bc-1d9f04cf04a4"
id="INV-dc23b25d-4aa8-4a61-b9bc-1d9f04cf04a4"></a>The table that
follows enumerates adverse events that occurred at an incidence of
1% or more, and were more frequent than in the placebo group, among
nefazodone-treated patients who participated in short-term (6- to
8-week) placebo-controlled trials in which patients were dosed with
nefazodone hydrochloride to ranges of 300 to 600 mg/day. This table
shows the percentage of patients in each group who had at least one
episode of an event at some time during their treatment. Reported
adverse events were classified using standard COSTART-based
Dictionary terminology.</p>
<p><a name="INV-f92ab6e2-6f12-4e37-9845-c78bd84394b3" id=
"INV-f92ab6e2-6f12-4e37-9845-c78bd84394b3"></a>The prescriber
should be aware that these figures cannot be used to predict the
incidence of side effects in the course of usual medical practice
where patient characteristics and other factors differ from those
which prevailed in the clinical trials. Similarly, the cited
frequencies cannot be compared with figures obtained from other
clinical investigations involving different treatments, uses, and
investigators. The cited figures, however, do provide the
prescribing physician with some basis for estimating the relative
contribution of drug and nondrug factors to the side-effect
incidence rate in the population studied.</p>
<a name="INV-8c273ae0-5961-40b8-8e0a-04dddcfbda2d" id=
"INV-8c273ae0-5961-40b8-8e0a-04dddcfbda2d"></a>
<div class="scrollingtable">
<table frame="void">
<colgroup>
<col width="156px">
<col width="156px">
<col width="156px">
<col width="156px"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center" colspan="4" valign="middle">
<span class="Bold">Treatment Emergent Adverse Experience Incidence
in 6 to 8</span><span class="Bold">Week Placebo</span><span class=
"Bold">-</span><span class="Bold">Controlled Clinical
Trials<span class="Sup">1</span>, NEFAZODONE</span> <span class=
"Bold">300 to 600 mg/day</span> <span class="Bold">Dose</span>
<span class="Bold">Range</span></td>
</tr>
<tr>
<td class="Botrule" colspan="2" valign="middle"></td>
<td class="Botrule" align="center" colspan="2" valign="middle">
Percent of Patients</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Nefazodone</td>
<td class="Botrule" align="center" valign="middle">Placebo</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Body System</td>
<td class="Botrule" valign="middle">Preferred Term</td>
<td class="Botrule" align="center" valign="middle">(n = 393)</td>
<td class="Botrule" align="center" valign="middle">(n = 394)</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Body as a Whole</td>
<td class="Botrule" valign="middle">Headache</td>
<td class="Botrule" align="center" valign="middle">36</td>
<td class="Botrule" align="center" valign="middle">33</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Asthenia</td>
<td class="Botrule" align="center" valign="middle">11</td>
<td class="Botrule" align="center" valign="middle">5</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Infection</td>
<td class="Botrule" align="center" valign="middle">8</td>
<td class="Botrule" align="center" valign="middle">6</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Flu syndrome</td>
<td class="Botrule" align="center" valign="middle">3</td>
<td class="Botrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Chills</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Fever</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Neck rigidity</td>
<td class="Botrule" align="center" valign="middle">1</td>
<td class="Botrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Cardiovascular</td>
<td class="Botrule" valign="middle">Postural hypotension</td>
<td class="Botrule" align="center" valign="middle">4</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Hypotension</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Dermatological</td>
<td class="Botrule" valign="middle">Pruritus</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Rash</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Gastrointestinal</td>
<td class="Botrule" valign="middle">Dry mouth</td>
<td class="Botrule" align="center" valign="middle">25</td>
<td class="Botrule" align="center" valign="middle">13</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Nausea</td>
<td class="Botrule" align="center" valign="middle">22</td>
<td class="Botrule" align="center" valign="middle">12</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Constipation</td>
<td class="Botrule" align="center" valign="middle">14</td>
<td class="Botrule" align="center" valign="middle">8</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Dyspepsia</td>
<td class="Botrule" align="center" valign="middle">9</td>
<td class="Botrule" align="center" valign="middle">7</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Diarrhea</td>
<td class="Botrule" align="center" valign="middle">8</td>
<td class="Botrule" align="center" valign="middle">7</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Increased appetite</td>
<td class="Botrule" align="center" valign="middle">5</td>
<td class="Botrule" align="center" valign="middle">3</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Nausea &amp; vomiting</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Metabolic</td>
<td class="Botrule" valign="middle">Peripheral edema</td>
<td class="Botrule" align="center" valign="middle">3</td>
<td class="Botrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Thirst</td>
<td class="Botrule" align="center" valign="middle">1</td>
<td class="Botrule" align="center" valign="middle"><span class=
"Bold">&lt;</span> 1</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Musculoskeletal</td>
<td class="Botrule" valign="middle">Arthralgia</td>
<td class="Botrule" align="center" valign="middle">1</td>
<td class="Botrule" align="center" valign="middle"><span class=
"Bold">&lt;</span> 1</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Nervous</td>
<td class="Botrule" valign="middle">Somnolence</td>
<td class="Botrule" align="center" valign="middle">25</td>
<td class="Botrule" align="center" valign="middle">14</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Dizziness</td>
<td class="Botrule" align="center" valign="middle">17</td>
<td class="Botrule" align="center" valign="middle">5</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Insomnia</td>
<td class="Botrule" align="center" valign="middle">11</td>
<td class="Botrule" align="center" valign="middle">9</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Lightheadedness</td>
<td class="Botrule" align="center" valign="middle">10</td>
<td class="Botrule" align="center" valign="middle">3</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Confusion</td>
<td class="Botrule" align="center" valign="middle">7</td>
<td class="Botrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Memory impairment</td>
<td class="Botrule" align="center" valign="middle">4</td>
<td class="Botrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Paresthesia</td>
<td class="Botrule" align="center" valign="middle">4</td>
<td class="Botrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Vasodilatation <span class=
"Sup">2</span></td>
<td class="Botrule" align="center" valign="middle">4</td>
<td class="Botrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Abnormal dreams</td>
<td class="Botrule" align="center" valign="middle">3</td>
<td class="Botrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Concentration decreased</td>
<td class="Botrule" align="center" valign="middle">3</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Ataxia</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Incoordination</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Psychomotor retardation</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Tremor</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Hypertonia</td>
<td class="Botrule" align="center" valign="middle">1</td>
<td class="Botrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Libido decreased</td>
<td class="Botrule" align="center" valign="middle">1</td>
<td class="Botrule" align="center" valign="middle"><span class=
"Bold">&lt;</span> 1</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Respiratory</td>
<td class="Botrule" valign="middle">Pharyngitis</td>
<td class="Botrule" align="center" valign="middle">6</td>
<td class="Botrule" align="center" valign="middle">5</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Cough increased</td>
<td class="Botrule" align="center" valign="middle">3</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Special Senses</td>
<td class="Botrule" valign="middle">Blurred vision</td>
<td class="Botrule" align="center" valign="middle">9</td>
<td class="Botrule" align="center" valign="middle">3</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Abnormal vision <span class=
"Sup">3</span></td>
<td class="Botrule" align="center" valign="middle">7</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Tinnitus</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Taste perversion</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Visual field defect</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">0</td>
</tr>
<tr>
<td class="Botrule" valign="middle">Urogenital</td>
<td class="Botrule" valign="middle">Urinary frequency</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Urinary tract infection</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Urinary retention</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Vaginitis <span class=
"Sup">4</span></td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule" align="center" valign="middle">1</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="middle"></td>
<td class="Botrule" valign="middle">Breast pain <span class=
"Sup">4</span></td>
<td class="Botrule" align="center" valign="middle">1</td>
<td class="Botrule" align="center" valign="middle"><span class=
"Bold">&lt;</span> 1</td>
</tr>
</tbody>
</table>
</div>
<p><a name="INV-f6b157d7-542c-464b-b229-32c1becf2006" id=
"INV-f6b157d7-542c-464b-b229-32c1becf2006"></a><span class=
"Sup">1</span>Events reported by at least 1% of patients treated
with nefazodone and more frequent than the placebo group are
included; incidence is rounded to the nearest 1% ( <span class=
"Bold">&lt;</span> 1% indicates an incidence less than 0.5%).
Events for which the nefazodone incidence was equal to or less than
placebo are not listed in the table, but included the following:
abdominal pain, pain, back pain, accidental injury, chest pain,
neck pain, palpitation, migraine, sweating, flatulence, vomiting,
anorexia, tooth disorder, weight gain, edema, myalgia, cramp,
agitation, anxiety, depression, hypesthesia, CNS stimulation,
dysphoria, emotional lability, sinusitis, rhinitis,
dysmenorrhea<span class="Sup">4</span>, dysuria.</p>
<p><a name="INV-812ca04a-128e-42bb-a6a6-8390bdd357fd" id=
"INV-812ca04a-128e-42bb-a6a6-8390bdd357fd"></a><span class=
"Sup">2</span>Vasodilatation—flushing, feeling warm.</p>
<p><a name="INV-1c163976-ed44-4968-b401-17bc7b8acfb8" id=
"INV-1c163976-ed44-4968-b401-17bc7b8acfb8"></a><span class=
"Sup">3</span>Abnormal vision—scotoma, visual trails.</p>
<p><a name="INV-c3635aa4-4ccb-4adb-803a-a22a54ab3975" id=
"INV-c3635aa4-4ccb-4adb-803a-a22a54ab3975"></a><span class=
"Sup">4</span>Incidence adjusted for gender.</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-1308d1d4-d5a8-4170-b66a-941269464672" id=
"INV-1308d1d4-d5a8-4170-b66a-941269464672"></a> <a name=
"section-10.2.3" id="section-10.2.3"></a>
<h3><span class="Italics">Dose Dependency of Adverse
Events</span></h3>
<p class="First"><a name="INV-1ffcdb3e-dfb8-4ab9-b6a9-bcd171a2bfcf"
id="INV-1ffcdb3e-dfb8-4ab9-b6a9-bcd171a2bfcf"></a>The table that
follows enumerates adverse events that were more frequent in the
nefazodone hydrochloride dose range of 300 to 600 mg/day than in
the nefazodone dose range of up to 300 mg/day. This table shows
only those adverse events for which there was a statistically
significant difference (p ≤ 0.05) in incidence between the
nefazodone dose ranges as well as a difference between the high
dose range and placebo.</p>
<a name="INV-d45aa06a-3b51-4fc7-b738-f06b072a5113" id=
"INV-d45aa06a-3b51-4fc7-b738-f06b072a5113"></a>
<div class="scrollingtable">
<table border="1" frame="border">
<colgroup>
<col width="124px">
<col width="124px">
<col width="124px">
<col width="124px">
<col width="124px"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="center" colspan="5" valign=
"middle">Dose Dependency of Adverse Events in Placebo-Controlled
Trials<span class="Sup">1</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="2" valign=
"middle"></td>
<td class="Botrule Rrule" colspan="3" valign="middle"><span class=
"Italics">Percent of Patients</span></td>
</tr>
<tr>
<td class="Botrule Lrule" colspan="2" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">Nefazodone</td>
<td class="Botrule" align="center" valign="middle">Nefazodone</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle">Body System</td>
<td class="Botrule" valign="middle">Preferred Term</td>
<td class="Botrule" align="center" valign="middle">300 to 600
mg/day (n = 209)</td>
<td class="Botrule" align="center" valign="middle">≤ 300 mg/day (n
= 211)</td>
<td class="Botrule Rrule" align="center" valign="middle">Placebo (n
= 212)</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle">Gastrointestinal</td>
<td class="Botrule" valign="middle">Nausea</td>
<td class="Botrule" align="center" valign="middle">23</td>
<td class="Botrule" align="center" valign="middle">14</td>
<td class="Botrule Rrule" align="center" valign="middle">12</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"></td>
<td class="Botrule" valign="middle">Constipation</td>
<td class="Botrule" align="center" valign="middle">17</td>
<td class="Botrule" align="center" valign="middle">10</td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle">Nervous</td>
<td class="Botrule" valign="middle">Somnolence</td>
<td class="Botrule" align="center" valign="middle">28</td>
<td class="Botrule" align="center" valign="middle">16</td>
<td class="Botrule Rrule" align="center" valign="middle">13</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"></td>
<td class="Botrule" valign="middle">Dizziness</td>
<td class="Botrule" align="center" valign="middle">22</td>
<td class="Botrule" align="center" valign="middle">11</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"></td>
<td class="Botrule" valign="middle">Confusion</td>
<td class="Botrule" align="center" valign="middle">8</td>
<td class="Botrule" align="center" valign="middle">2</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle">Special Senses</td>
<td class="Botrule" valign="middle">Abnormal vision</td>
<td class="Botrule" align="center" valign="middle">10</td>
<td class="Botrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"></td>
<td class="Botrule" valign="middle">Blurred vision</td>
<td class="Botrule" align="center" valign="middle">9</td>
<td class="Botrule" align="center" valign="middle">3</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="middle"></td>
<td class="Botrule" valign="middle">Tinnitus</td>
<td class="Botrule" align="center" valign="middle">3</td>
<td class="Botrule" align="center" valign="middle">0</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
</tbody>
</table>
</div>
<p><a name="INV-5fdb3976-98b1-420f-995d-24000df73c04" id=
"INV-5fdb3976-98b1-420f-995d-24000df73c04"></a><span class=
"Sup">1</span>Events for which there was a statistically
significant difference (p ≤ 0.05) between the nefazodone dose
groups.</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-71f923e7-091f-439a-9c41-ceee8db8c1e1" id=
"INV-71f923e7-091f-439a-9c41-ceee8db8c1e1"></a> <a name=
"section-10.2.4" id="section-10.2.4"></a>
<h3><span class="Italics">Visual Disturbances</span></h3>
<p class="First"><a name="INV-df197c38-341b-4310-b2e3-e5b52c0a779a"
id="INV-df197c38-341b-4310-b2e3-e5b52c0a779a"></a>In controlled
clinical trials, blurred vision occurred in 9% of
nefazodone-treated patients compared to 3% of placebo-treated
patients. In these same trials, abnormal vision, including
scotomata and visual trails, occurred in 7% of nefazodone-treated
patients compared to 1% of placebo-treated (see Treatment- Emergent
Adverse Experience table, above). Dose-dependencey was observed for
these events in these trials, with none of the scotomata and visual
trails at doses below 300 mg/day. However, scotomata and visual
trails observed at doses below 300 mg/day have been reported in
postmarketing experience with nefazodone. (See <span class=
"Bold">PRECAUTIONS: Information for Patients</span>.)</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-90126ac8-223c-4063-b906-85fbd187df56" id=
"INV-90126ac8-223c-4063-b906-85fbd187df56"></a> <a name=
"section-10.2.5" id="section-10.2.5"></a>
<h3><span class="Italics">Vital Sign Changes</span></h3>
<p class="First"><a name="INV-f55ea6a1-d5cf-470f-b06a-9baf0bebaa40"
id="INV-f55ea6a1-d5cf-470f-b06a-9baf0bebaa40"></a>(See <span class=
"Bold">PRECAUTIONS</span>, <span class="Italics">Postural
Hypotension</span>.)</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-77e4c0d3-0cfb-40bb-b1b8-8486d19784b1" id=
"INV-77e4c0d3-0cfb-40bb-b1b8-8486d19784b1"></a> <a name=
"section-10.2.6" id="section-10.2.6"></a>
<h3><span class="Italics">Weight Changes</span></h3>
<p class="First"><a name="INV-e8b8fbdf-05c4-4db9-9551-ce13bc66f456"
id="INV-e8b8fbdf-05c4-4db9-9551-ce13bc66f456"></a>In a pooled
analysis of placebo-controlled premarketing studies, there were no
differences between nefazodone and placebo groups in the
proportions of patients meeting criteria for potentially important
increases or decreases in body weight (a change of ≥ 7%).</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-9b67b868-d74a-4792-8ada-88e5406807a8" id=
"INV-9b67b868-d74a-4792-8ada-88e5406807a8"></a> <a name=
"section-10.2.7" id="section-10.2.7"></a>
<h3><span class="Italics">Laboratory Changes</span></h3>
<p class="First"><a name="INV-00e0f0ef-589d-4047-8cb2-e5418d965f86"
id="INV-00e0f0ef-589d-4047-8cb2-e5418d965f86"></a>Of the serum
chemistry, serum hematology, and urinalysis parameters monitored
during placebo-controlled premarketing studies with nefazodone, a
pooled analysis revealed a statistical trend between nefazodone and
placebo for hematocrit, i.e., 2.8% of nefazodone patients met
criteria for a potentially important decrease in hematocrit (≤ 37%
male or ≤ 32% female) compared to 1.5% of placebo patients (0.05
<span class="Bold">&lt;</span> p ≤ 0.1). Decreases in hematocrit,
presumably dilutional, have been reported with many other drugs
that block alpha<span class="Sub">1</span>-adrenergic receptors.
There was no apparent clinical significance of the observed changes
in the few patients meeting these criteria.</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-895a746d-0e49-47e8-a64e-48d565c51ff7" id=
"INV-895a746d-0e49-47e8-a64e-48d565c51ff7"></a> <a name=
"section-10.2.8" id="section-10.2.8"></a>
<h3><span class="Italics">ECG Changes</span></h3>
<p class="First"><a name="INV-eeb9cfb6-726e-484d-96d0-ab9b819c2f39"
id="INV-eeb9cfb6-726e-484d-96d0-ab9b819c2f39"></a>Of the ECG
parameters monitored during placebo-controlled premarketing studies
with nefazodone, a pooled analysis revealed a statistically
significant difference between nefazodone and placebo for sinus
bradycardia, i.e., 1.5% of nefazodone patients met criteria for a
potentially important decrease in heart rate (≤ 50 bpm and a
decrease of ≥ 15 bpm) compared to 0.4% of placebo patients (p
<span class="Bold">&lt;</span> 0.05). There was no obvious clinical
significance of the observed changes in the few patients meeting
these criteria.</p>
</div>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-462776f6-bc8c-4edd-9440-c4a45824ac77" id=
"INV-462776f6-bc8c-4edd-9440-c4a45824ac77"></a> <a name=
"section-10.3" id="section-10.3"></a>
<h2>Other Events Observed During the Premarketing Evaluation of
Nefazodone</h2>
<p class="First"><a name="INV-0ad11a6a-1877-40ea-bb82-9e4bcfd36842"
id="INV-0ad11a6a-1877-40ea-bb82-9e4bcfd36842"></a>During its
premarketing assessment, multiple doses of nefazodone hydrochloride
were administered to 3496 patients in clinical studies, including
more than 250 patients treated for at least one year. The
conditions and duration of exposure to nefazodone varied greatly,
and included (in overlapping categories) open and double-blind
studies, uncontrolled and controlled studies, inpatient and
outpatient studies, fixed dose and titration studies. Untoward
events associated with this exposure were recorded by clinical
investigators using terminology of their own choosing.
Consequently, it is not possible to provide a meaningful estimate
of the proportion of individuals experiencing adverse events
without first grouping similar types of untoward events into a
smaller number of standardized event categories.</p>
<p><a name="INV-0ece7423-a102-488d-b11b-28e5057f9571" id=
"INV-0ece7423-a102-488d-b11b-28e5057f9571"></a>In the tabulations
that follow, reported adverse events were classified using standard
COSTART-based Dictionary terminology. The frequencies presented,
therefore, represent the proportion of the 3496 patients exposed to
multiple doses of nefazodone who experienced an event of the type
cited on at least one occasion while receiving nefazodone. All
reported events are included except those already listed in the
Treatment-Emergent Adverse Experience Incidence table, those events
listed in other safety-related sections of this insert, those
adverse experiences subsumed under COSTART terms that are either
overly general or excessively specific so as to be uninformative,
those events for which a drug cause was very remote, and those
events which were not serious and occurred in fewer than two
patients.</p>
<p><a name="INV-1086f7c4-2da6-4a7f-84ed-f9a6e2067542" id=
"INV-1086f7c4-2da6-4a7f-84ed-f9a6e2067542"></a>It is important to
emphasize that, although the events reported occurred during
treatment with nefazodone, they were not necessarily caused by
it.</p>
<p><a name="INV-4e4bb2c9-d4b8-4e2c-9a01-5981b000570e" id=
"INV-4e4bb2c9-d4b8-4e2c-9a01-5981b000570e"></a>Events are further
categorized by body system and listed in order of decreasing
frequency according to the following definitions: frequent adverse
events are those occurring on one or more occasions in at least
1/100 patients (only those not already listed in the tabulated
results from placebo-controlled trials appear in this listing);
infrequent adverse events are those occurring in 1/100 to 1/1000
patients; rare events are those occurring in fewer than 1/1000
patients.</p>
<p><a name="INV-1566a97b-e564-41ec-bbd4-5570276fea60" id=
"INV-1566a97b-e564-41ec-bbd4-5570276fea60"></a><span class=
"Italics">Body as a whole—Infrequent:</span> allergic reaction,
malaise, photosensitivity reaction, face edema, hang-over effect,
abdomen enlarged, hernia, pelvic pain, and halitosis. <span class=
"Italics">Rare:</span> cellulitis.</p>
<p><a name="INV-bba3d08a-20be-4600-b259-487a2c063504" id=
"INV-bba3d08a-20be-4600-b259-487a2c063504"></a><span class=
"Italics">Cardiovascular system—Infrequent:</span> tachycardia,
hypertension, syncope, ventricular extrasystoles, and angina
pectoris. <span class="Italics">Rare:</span> AV block, congestive
heart failure, hemorrhage, pallor, and varicose vein.</p>
<p><a name="INV-67405152-1834-4f87-9f80-5a2dba3a412a" id=
"INV-67405152-1834-4f87-9f80-5a2dba3a412a"></a><span class=
"Italics">Dermatological system—Infrequent:</span> dry skin, acne,
alopecia, urticaria, maculopapular rash, vesiculobullous rash, and
eczema.</p>
<p><a name="INV-685b654e-2a3d-428a-981d-c193d0b0ffa9" id=
"INV-685b654e-2a3d-428a-981d-c193d0b0ffa9"></a><span class=
"Italics">Gastrointestinal system—Frequent:</span> gastroenteritis.
<span class="Italics">Infrequent</span>: eructation, periodontal
abscess, abnormal liver function tests, gingivitis, colitis,
gastritis, mouth ulceration, stomatitis, esophagitis, peptic ulcer,
and rectal hemorrhage. <span class="Italics">Rare:</span>
glossitis, hepatitis, dysphagia, gastrointestinal hemorrhage, oral
moniliasis, and ulcerative colitis.</p>
<p><a name="INV-797f4534-c2c6-484f-b80f-afd9285d3c9b" id=
"INV-797f4534-c2c6-484f-b80f-afd9285d3c9b"></a><span class=
"Italics">Hemic and lymphatic system—Infrequent</span>: ecchymosis,
anemia, leukopenia, and lymphadenopathy.</p>
<p><a name="INV-a88b7a2c-fbf6-4bd7-92e3-f7ca0cc982f8" id=
"INV-a88b7a2c-fbf6-4bd7-92e3-f7ca0cc982f8"></a><span class=
"Italics">Metabolic and nutritional system—Infrequent:</span>
weight loss, gout, dehydration, lactic dehydrogenase increased,
SGOT increased, and SGPT increased. <span class=
"Italics">Rare:</span> hypercholesteremia and hypoglycemia.</p>
<p><a name="INV-6d508720-a54b-4d06-814d-ee6ce5cff1e9" id=
"INV-6d508720-a54b-4d06-814d-ee6ce5cff1e9"></a><span class=
"Italics">Musculoskeletal system—Infrequent:</span> arthritis,
tenosynovitis, muscle stiffness, and bursitis. <span class=
"Italics">Rare:</span> tendinous contracture.</p>
<p><a name="INV-8320532b-002f-446e-8bb9-e5a1370a6b33" id=
"INV-8320532b-002f-446e-8bb9-e5a1370a6b33"></a><span class=
"Italics">Nervous system—Infrequent:</span> vertigo, twitching,
depersonalization, hallucinations, suicide attempt, apathy,
euphoria, hostility, suicidal thoughts, abnormal gait, thinking
abnormal, attention decreased, derealization, neuralgia, paranoid
reaction, dysarthria, increased libido, suicide, and myoclonus.
<span class="Italics">Rare:</span> hyperkinesia, increased
salivation, cerebrovascular accident, hyperesthesia, hypotonia,
ptosis, and neuroleptic malignant syndrome.</p>
<p><a name="INV-abf5bbf4-caf2-45a6-8707-f41777cbf0c0" id=
"INV-abf5bbf4-caf2-45a6-8707-f41777cbf0c0"></a><span class=
"Italics">Respiratory system—Frequent:</span> dyspnea and
bronchitis. <span class="Italics">Infrequent</span><span class=
"Italics">:</span> asthma, pneumonia, laryngitis, voice alteration,
epistaxis, hiccup. <span class="Italics">Rare:</span>
hyperventilation and yawn.</p>
<p><a name="INV-441cb9ee-4018-4f30-86c8-72eb4abd717d" id=
"INV-441cb9ee-4018-4f30-86c8-72eb4abd717d"></a><span class=
"Italics">Special senses—Frequent:</span> eye pain. <span class=
"Italics">Infrequent</span><span class="Italics">:</span> dry eye,
ear pain, abnormality of accommodation, diplopia, conjunctivitis,
mydriasis, keratoconjunctivitis, hyperacusis, and photophobia.
<span class="Italics">Rare:</span> deafness, glaucoma, night
blindness, and taste loss.</p>
<p><a name="INV-6b64e3fc-5186-47b5-ba4b-e2963536066f" id=
"INV-6b64e3fc-5186-47b5-ba4b-e2963536066f"></a><span class=
"Italics">Urogenital system—Frequent</span><span class=
"Italics">:</span> impotence <span class="Sup">a</span>.
<span class="Italics">Infrequent</span><span class=
"Italics">:</span> cystitis, urinary urgency,
metrorrhagia<span class="Sup">a</span>, amenorrhea<span class=
"Sup">a</span>, polyuria, vaginal hemorrhage<span class=
"Sup">a</span>, breast enlargement<span class="Sup">a</span>,
menorrhagia<span class="Sup">a</span>, urinary incontinence,
abnormal ejaculation<span class="Sup">a</span>, hematuria,
nocturia, and kidney calculus. <span class="Italics">Rare:</span>
uterine fibroids enlarged<span class="Sup">a</span>, uterine
hemorrhage<span class="Sup">a</span>, anorgasmia, and oliguria.</p>
<p><a name="INV-20e1eadf-ba7a-4b7c-8415-08c4d7ec777f" id=
"INV-20e1eadf-ba7a-4b7c-8415-08c4d7ec777f"></a><span class=
"Sup">a</span>Adjusted for gender.</p>
</div>
<div class="Section" data-sectioncode="34084-4"><a name=
"INV-dc8cbdeb-e10e-4223-9ed9-fbfc69363dc2" id=
"INV-dc8cbdeb-e10e-4223-9ed9-fbfc69363dc2"></a> <a name=
"section-10.4" id="section-10.4"></a>
<h2>Postintroduction Clinical Experience</h2>
<p class="First"><a name="INV-9aaddb1f-27bb-4c0a-975e-e2307cafdb95"
id="INV-9aaddb1f-27bb-4c0a-975e-e2307cafdb95"></a>Postmarketing
experience with nefazodone has shown an adverse experience profile
similar to that seen during the premarketing evaluation of
nefazodone. Voluntary reports of adverse events temporally
associated with nefazodone have been received since market
introduction that are not listed above and for which a causal
relationship has not been established. These include: Anaphylactic
reactions; angioedema; convulsions (including grand mal seizures);
galactorrhea; gynecomastia (male); hyponatremia; liver necrosis and
liver failure, in some cases leading to liver transplantation
and/or death (see <span class="Bold">WARNINGS</span>); priapism
(see <span class="Bold">PRECAUTIONS</span>); prolactin increased;
rhabdomyolysis involving patients receiving the combination of
nefazodone and lovastatin or simvastatin (see <span class=
"Bold">PRECAUTIONS</span>); serotonin syndrome; and Stevens-Johnson
syndrome; and thrombocytopenia.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DRUG ABUSE AND DEPENDENCE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42227-9"><a name="INV-7d038679-3629-45d3-8b1e-022945fc0ec5" id=
"INV-7d038679-3629-45d3-8b1e-022945fc0ec5"></a> <a name=
"section-11" id="section-11"></a>
<div class="Section" data-sectioncode="34085-1"><a name=
"INV-8ee43061-7056-48d6-998d-ca006b2ac0fc" id=
"INV-8ee43061-7056-48d6-998d-ca006b2ac0fc"></a> <a name=
"section-11.1" id="section-11.1"></a>
<h2>Controlled Substance Class</h2>
<p class="First"><a name="INV-b07d0c9b-07b0-4e17-8a3d-17f545a98779"
id="INV-b07d0c9b-07b0-4e17-8a3d-17f545a98779"></a>Nefazodone
hydrochloride is not a controlled substance.</p>
</div>
<div class="Section" data-sectioncode="42227-9"><a name=
"INV-2eea5bfb-7d67-4c21-8666-246b7e0a5c1b" id=
"INV-2eea5bfb-7d67-4c21-8666-246b7e0a5c1b"></a> <a name=
"section-11.2" id="section-11.2"></a>
<h2>Physical and Psychological Dependence</h2>
<p class="First"><a name="INV-299d0a5e-024e-4679-9083-374049899323"
id="INV-299d0a5e-024e-4679-9083-374049899323"></a>In animal
studies, nefazodone did not act as a reinforcer for intravenous
self-administration in monkeys trained to self-administer cocaine,
suggesting no abuse liability. In a controlled study of abuse
liability in human subjects, nefazodone showed no potential for
abuse.</p>
<p><a name="INV-d2681335-2877-4f62-9c51-57eafc255df5" id=
"INV-d2681335-2877-4f62-9c51-57eafc255df5"></a>Nefazodone has not
been systematically studied in humans for its potential for
tolerance, physical dependence, or withdrawal. While the
premarketing clinical experience with nefazodone did not reveal any
tendency for a withdrawal syndrome or any drug-seeking behavior, it
is not possible to predict on the basis of this limited experience
the extent to which a CNS-active drug will be misused, diverted,
and/or abused once marketed. Consequently, physicians should
carefully evaluate patients for a history of drug abuse and follow
such patients closely, observing them for signs of misuse or abuse
of nefazodone (e.g., development of tolerance, dose escalation,
drug-seeking behavior).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="INV-6c71168a-bd11-42f2-9d07-1fc8195bed24" id=
"INV-6c71168a-bd11-42f2-9d07-1fc8195bed24"></a> <a name=
"section-12" id="section-12"></a>
<div class="Section" data-sectioncode="34088-5"><a name=
"INV-aea44913-ee1a-4a26-8dd1-5509332a177f" id=
"INV-aea44913-ee1a-4a26-8dd1-5509332a177f"></a> <a name=
"section-12.1" id="section-12.1"></a>
<h2>Human Experience</h2>
<p class="First"><a name="INV-240bd5ce-b3ed-4030-a475-021d688aee02"
id="INV-240bd5ce-b3ed-4030-a475-021d688aee02"></a>In premarketing
clinical studies, there were seven reports of nefazodone overdose
alone or in combination with other pharmacological agents. The
amount of nefazodone ingested ranged from 1000 mg to 11,200 mg.
Commonly reported symptoms from overdose of nefazodone included
nausea, vomiting, and somnolence. One nonstudy participant took
2000 to 3000 mg of nefazodone with methocarbamol and alcohol; this
person reportedly experienced a convulsion (type not documented).
None of these patients died.</p>
<p><a name="INV-3a5ded4e-fa7d-48ee-87cc-b6df77f88509" id=
"INV-3a5ded4e-fa7d-48ee-87cc-b6df77f88509"></a>In postmarketing
experience, overdose with nefazodone alone and in combination with
alcohol and/or other substances has been reported. Commonly
reported symptoms were similar to those reported from overdose in
premarketing experience. While there have been rare reports of
fatalities in patients taking overdoses of nefazodone,
predominantly in combination with alcohol and/or other substances,
no causal relationship to nefazodone has been established.</p>
</div>
<div class="Section" data-sectioncode="34088-5"><a name=
"INV-fd9631a8-4d09-4a96-a324-96421d4f1e6a" id=
"INV-fd9631a8-4d09-4a96-a324-96421d4f1e6a"></a> <a name=
"section-12.2" id="section-12.2"></a>
<h2>Overdosage Management</h2>
<p class="First"><a name="INV-694c5783-bae9-48f1-b464-6fbe8947afb9"
id="INV-694c5783-bae9-48f1-b464-6fbe8947afb9"></a>Ensure an
adequate airway, oxygenation, and ventilation. Monitor cardiac
rhythm and vital signs. General supportive and symptomatic measures
are also recommended. Induction of emesis is not recommended.
Gastric lavage with a large-bore orogastric tube with appropriate
airway protection, if needed, may be indicated if performed soon
after ingestion, or in symptomatic patients.</p>
<p><a name="INV-3aa187c9-3c6d-4bf2-b5ee-67e8c5620e51" id=
"INV-3aa187c9-3c6d-4bf2-b5ee-67e8c5620e51"></a>Activated charcoal
should be administered. Due to the wide distribution of nefazodone
in body tissues, forced diuresis, dialysis, hemoperfusion, and
exchange transfusion are unlikely to be of benefit. No specific
antidotes for nefazodone are known.</p>
<p><a name="INV-22c9f64c-34c3-4029-802f-2b6926f21827" id=
"INV-22c9f64c-34c3-4029-802f-2b6926f21827"></a>In managing
overdosage, consider the possibility of multiple drug involvement.
The physician should consider contacting a poison control center
for additional information on the treatment of any overdose.
Telephone numbers for certified poison control centers are listed
in the <span class="Italics">Physicians’ Desk Reference</span>
(PDR).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="INV-598a2a37-fc56-45bb-807e-d53eda3afc53" id=
"INV-598a2a37-fc56-45bb-807e-d53eda3afc53"></a> <a name=
"section-13" id="section-13"></a>
<p class="First"><a name="INV-e5397048-e258-483b-b440-137866416d57"
id="INV-e5397048-e258-483b-b440-137866416d57"></a>When deciding
among alternative treatments available for depression, the
prescriber should consider the risk of hepatic failure associated
with nefazodone hydrochloride tablets, USP treatment (see
<span class="Bold">WARNINGS</span>).</p>
<p><a name="INV-bbdb0ead-e069-46bc-8964-4eb59861553b" id=
"INV-bbdb0ead-e069-46bc-8964-4eb59861553b"></a><span class=
"Bold">Initial Treatment</span></p>
<p><a name="INV-36208fd7-7183-4d9b-8ffe-c0b4a76605e7" id=
"INV-36208fd7-7183-4d9b-8ffe-c0b4a76605e7"></a>The recommended
starting dose for nefazodone hydrochloride tablet, USP is 200
mg/day, administered in two divided doses (BID). In the controlled
clinical trials establishing the antidepressant efficacy of
nefazodone, the effective dose range was generally 300 to 600
mg/day. Consequently, most patients, depending on tolerability and
the need for further clinical effect, should have their dose
increased. Dose increases should occur in increments of 100 mg/day
to 200 mg/day, again on a BID schedule, at intervals of no less
than 1 week. As with all antidepressants, several weeks on
treatment may be required to obtain a full antidepressant
response.</p>
<p><a name="INV-6ba8da59-9400-4b20-81a0-55bf782c8a37" id=
"INV-6ba8da59-9400-4b20-81a0-55bf782c8a37"></a><span class=
"Bold">Dosage for Elderly or Debilitated Patients</span></p>
<p><a name="INV-a6fdb546-20ac-48a3-ac9a-76e552b72dec" id=
"INV-a6fdb546-20ac-48a3-ac9a-76e552b72dec"></a>The recommended
initial dose for elderly or debilitated patients is 100 mg/day,
administered in two divided doses (BID). These patients often have
reduced nefazodone clearance and/or increased sensitivity to the
side effects of CNS-active drugs. It may also be appropriate to
modify the rate of subsequent dose titration. As steady-state
plasma levels do not change with age, the final target dose based
on a careful assessment of the patient’s clinical response may be
similar in healthy younger and older patients.</p>
<p><a name="INV-09f20666-153a-44e5-9067-c862bb3ce915" id=
"INV-09f20666-153a-44e5-9067-c862bb3ce915"></a><span class=
"Bold">Maintenance/Continuation/Extended Treatment</span></p>
<p><a name="INV-6aa2f5f8-a641-4e53-80c9-e5ae0cb3f90d" id=
"INV-6aa2f5f8-a641-4e53-80c9-e5ae0cb3f90d"></a>There is no body of
evidence available from controlled trials to indicate how long the
depressed patient should be treated with nefazodone. It is
generally agreed, however, that pharmacological treatment for acute
episodes of depression should continue for up to 6 months or
longer. Whether the dose of antidepressant needed to induce
remission is identical to the dose needed to maintain euthymia is
unknown. Systematic evaluation of the efficacy of nefazodone has
shown that efficacy is maintained for periods of up to 36 weeks
following 16 weeks of open-label acute treatment (treated for 52
weeks total) at dosages that averaged 438 mg/day. For most
patients, their maintenance dose was that associated with response
during acute treatment. (See <span class="Bold">CLINICAL
PHARMACOLOGY</span>.) The safety of nefazodone in long-term use is
supported by data from both double-blind and open-label trials
involving more than 250 patients treated for at least one year.</p>
<p><a name="INV-b8b12215-2041-4864-bc21-97d577d3f2c1" id=
"INV-b8b12215-2041-4864-bc21-97d577d3f2c1"></a><span class=
"Bold">Switching Patients to or from a Monoamine Oxidase
Inhibitor</span></p>
<p><a name="INV-8ed78301-13f1-4f46-8fe4-4979a4af1856" id=
"INV-8ed78301-13f1-4f46-8fe4-4979a4af1856"></a>At least 14 days
should elapse between discontinuation of an MAOI and initiation of
therapy with nefazodone. In addition, at least 7 days should be
allowed after stopping nefazodone before starting an MAOI.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HOW SUPPLIED</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="INV-0868a9d8-f955-4564-97d6-1ab9e983f25d" id=
"INV-0868a9d8-f955-4564-97d6-1ab9e983f25d"></a> <a name=
"section-14" id="section-14"></a>
<p class="First"><a name="INV-153a6e33-55a5-46a8-bbf9-f2d26198743d"
id="INV-153a6e33-55a5-46a8-bbf9-f2d26198743d"></a>Nefazodone
hydrochloride tablets, USP 50 mg are light pink colored, uncoated,
round tablets debossed with “RX 541” on one side and plain on the
other side. They are supplied as follows:</p>
<p><a name="INV-3bd1bd18-59e7-4e00-8ec7-d19625745674" id=
"INV-3bd1bd18-59e7-4e00-8ec7-d19625745674"></a><span class=
"Bold">NDC</span> 63304-541-30 unit of use bottles of 30</p>
<p><a name="INV-6b3fbe87-d787-4bee-b330-f837f25f816e" id=
"INV-6b3fbe87-d787-4bee-b330-f837f25f816e"></a><span class=
"Bold">NDC</span> 63304-541-05 bottles of 500</p>
<p><a name="INV-c7eb9b6d-7523-4af1-a3e7-d6a271b7305d" id=
"INV-c7eb9b6d-7523-4af1-a3e7-d6a271b7305d"></a>Nefazodone
hydrochloride tablets, USP 100 mg are white colored, uncoated,
round tablets debossed with “RX 542” and a scoreline on one side
and plain on the other side. They are supplied as follows:</p>
<p><a name="INV-c3cbce6b-4d4d-441e-a1e8-61f4451b25f6" id=
"INV-c3cbce6b-4d4d-441e-a1e8-61f4451b25f6"></a><span class=
"Bold">NDC</span> 63304-542-30 unit of use bottles of 30</p>
<p><a name="INV-bae8f5c0-e908-4836-bab3-090e600595f9" id=
"INV-bae8f5c0-e908-4836-bab3-090e600595f9"></a><span class=
"Bold">NDC</span> 63304-542-05 bottles of 500</p>
<p><a name="INV-0908526b-59bb-405e-899e-633fd559c584" id=
"INV-0908526b-59bb-405e-899e-633fd559c584"></a>Nefazodone
hydrochloride tablets, USP 150 mg are peach colored, uncoated,
round tablets debossed with “RX 543” and a scoreline on one side
and plain on the other side. They are supplied as follows:</p>
<p><a name="INV-4886eaab-fc7c-4c1d-965c-80c9dd246e06" id=
"INV-4886eaab-fc7c-4c1d-965c-80c9dd246e06"></a><span class=
"Bold">NDC</span> 63304-543-30 unit of use bottles of 30</p>
<p><a name="INV-af141102-5801-4374-9e81-de43c78ccf3a" id=
"INV-af141102-5801-4374-9e81-de43c78ccf3a"></a><span class=
"Bold">NDC</span> 63304-543-05 bottles of 500</p>
<p><a name="INV-5fb10990-4cf2-41a8-8f11-58c1ab44ab28" id=
"INV-5fb10990-4cf2-41a8-8f11-58c1ab44ab28"></a>Nefazodone
hydrochloride tablets, USP 200 mg are light yellow colored,
uncoated, round tablets debossed with “RX 544” on one side and
plain on the other side. They are supplied as follows:</p>
<p><a name="INV-af385f8d-479a-4ff3-9d1b-e7e086b26469" id=
"INV-af385f8d-479a-4ff3-9d1b-e7e086b26469"></a><span class=
"Bold">NDC</span> 63304-544-30 unit of use bottles of 30</p>
<p><a name="INV-1651c5c1-1898-42cc-9125-8fa10d1c9758" id=
"INV-1651c5c1-1898-42cc-9125-8fa10d1c9758"></a><span class=
"Bold">NDC</span> 63304-544-05 bottles of 500</p>
<p><a name="INV-89309022-4cd6-4bbc-8e24-78e5175ee50f" id=
"INV-89309022-4cd6-4bbc-8e24-78e5175ee50f"></a>Nefazodone
hydrochloride tablets, USP 250 mg are white colored, uncoated,
round tablets debossed with “RX 545” on one side and plain on the
other side. They are supplied as follows:</p>
<p><a name="INV-538adb9e-8481-4474-a380-2f224554e250" id=
"INV-538adb9e-8481-4474-a380-2f224554e250"></a><span class=
"Bold">NDC</span> 63304-545-30 unit of use bottles of 30</p>
<p><a name="INV-f466f670-88a6-4944-b312-1735bf4f0162" id=
"INV-f466f670-88a6-4944-b312-1735bf4f0162"></a><span class=
"Bold">NDC</span> 63304-545-05 bottles of 500</p>
<p><a name="INV-a8fc5e05-2295-4200-a135-2170f180077f" id=
"INV-a8fc5e05-2295-4200-a135-2170f180077f"></a>Dispense in a tight
container.</p>
<p><a name="INV-3d4a78ed-b4f1-44e2-84b0-1a5ca84566a8" id=
"INV-3d4a78ed-b4f1-44e2-84b0-1a5ca84566a8"></a>Store at 20-25°C
(68-77°F) [see USP Controlled Room Temperature].</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">REFERENCES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34093-5"><a name="INV-d63ef6b1-cdf7-4101-acb9-4633e6b56ebf" id=
"INV-d63ef6b1-cdf7-4101-acb9-4633e6b56ebf"></a> <a name=
"section-15" id="section-15"></a>
<p class="First"><a name="INV-516a3820-ab7e-43c9-85e4-73e05b8935aa"
id="INV-516a3820-ab7e-43c9-85e4-73e05b8935aa"></a>1. HALCION
<span class="Sup">®</span> and XANAX<span class="Sup">®</span> are
registered trademarks of Pharmacia and Upjohn.</p>
<p><a name="INV-04323971-b9ad-4c34-8062-1ed5a6caf0d9" id=
"INV-04323971-b9ad-4c34-8062-1ed5a6caf0d9"></a>2.
SELDANE<span class="Sup">®</span> is a registered trademark of
Hoechst Marion Roussel Inc. (now Aventis Pharmaceuticals).</p>
<p><a name="INV-264105c0-f218-4d7f-bb0d-412fad103b25" id=
"INV-264105c0-f218-4d7f-bb0d-412fad103b25"></a>3.
HISMANAL<span class="Sup">®</span> and PROPULSID<span class=
"Sup">®</span> are registered trademarks of Janssen Pharmaceutical
Products, L.P.</p>
<p><a name="INV-a902076c-1d29-4234-a5ce-0bcc982fd058" id=
"INV-a902076c-1d29-4234-a5ce-0bcc982fd058"></a>4. ORAP <span class=
"Sup">®</span> is a registered trademark of Gate Pharmaceuticals, a
division of Teva Pharmaceuticals USA.</p>
<p><a name="INV-a4c1468e-3316-4d8c-96e9-d162e5356145" id=
"INV-a4c1468e-3316-4d8c-96e9-d162e5356145"></a>5.
TEGRETOL<span class="Sup">®</span> is a registered trademark of
Novartis Pharmaceuticals Corporation.</p>
<p><a name="INV-c08acc7a-cec4-43c9-99d3-dd4ce1f1a593" id=
"INV-c08acc7a-cec4-43c9-99d3-dd4ce1f1a593"></a>Manufactured
for:</p>
<p><a name="INV-9fdb9ae7-2540-4980-af72-ad3babb97b07" id=
"INV-9fdb9ae7-2540-4980-af72-ad3babb97b07"></a>Ranbaxy
Pharmaceutical Inc.</p>
<p><a name="INV-50601e75-6886-47a8-bb90-1ae015f2c216" id=
"INV-50601e75-6886-47a8-bb90-1ae015f2c216"></a>Jacksonville FL,
32257 USA</p>
<p><a name="INV-8ff6f5e5-7ef8-44b1-b3ca-fcd57ad981e6" id=
"INV-8ff6f5e5-7ef8-44b1-b3ca-fcd57ad981e6"></a>By: Ranbaxy
Laboratories Limited</p>
<p><a name="INV-56cd4286-d12e-41f4-9631-7d4d2e68b9b0" id=
"INV-56cd4286-d12e-41f4-9631-7d4d2e68b9b0"></a>New Delhi – 110 019,
India</p>
<p><a name="INV-afbc1dbb-a04b-49f7-9cc8-edc9d2c76ded" id=
"INV-afbc1dbb-a04b-49f7-9cc8-edc9d2c76ded"></a>December 2008</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PATIENT INFORMATION ABOUT NEFAZODONE HYDROCHLORIDE
TABLETS, USP</a>
<div class="Section toggle-content closed"><a name=
"INV-476df126-c5ff-4c48-b4b9-815cf5c11248" id=
"INV-476df126-c5ff-4c48-b4b9-815cf5c11248"></a> <a name=
"section-16" id="section-16"></a>
<p class="First"><a name="INV-b8c0ac2c-38c7-41f8-b8d5-e061ddd13b7d"
id="INV-b8c0ac2c-38c7-41f8-b8d5-e061ddd13b7d"></a><span class=
"Bold">Read this information completely before using
nefazodone.</span> Read the information each time you get more
medicine. There may be new information. This leaflet provides a
summary about nefazodone and does not include everything there is
to know about your medicine. This information is not meant to take
the place of talking with your doctor.</p>
<p><a name="INV-1434b342-58ff-4385-8310-eb75da5cf5da" id=
"INV-1434b342-58ff-4385-8310-eb75da5cf5da"></a><span class=
"Bold">What is the most important information that I should know
about nefazodone?</span></p>
<p><a name="INV-15f944fc-3b6a-45c5-bfee-df38b8352be7" id=
"INV-15f944fc-3b6a-45c5-bfee-df38b8352be7"></a>Rarely, people who
take nefazodone can develop serious liver problems. <span class=
"Bold">If you get any of the following symptoms while taking
nefazodone, call your doctor right away</span> because you may be
developing a liver problem:</p>
<ul class="Disc">
<li>Yellowing of the skin or whites of eyes (jaundice)</li>
<li>Unusually dark urine</li>
<li>Loss of appetite that lasts several days or longer</li>
<li>Nausea</li>
<li>Abdominal (lower stomach) pain</li>
</ul>
<p><a name="INV-eee1055a-4119-4b9a-8b2a-1a2d0d9f8511" id=
"INV-eee1055a-4119-4b9a-8b2a-1a2d0d9f8511"></a>People who currently
have liver problems should not take nefazodone.</p>
<p><a name="INV-9f2edbb8-f6e2-43e5-9214-2fcad0dce4dd" id=
"INV-9f2edbb8-f6e2-43e5-9214-2fcad0dce4dd"></a><span class=
"Bold">What is nefazodone?</span></p>
<p><a name="INV-9d1ce853-dbd5-43bd-8536-9cedd6436b71" id=
"INV-9d1ce853-dbd5-43bd-8536-9cedd6436b71"></a>Nefazodone is a
medicine used to treat depression. Nefazodone is thought to treat
depression by correcting an imbalance in the amounts of certain
natural chemicals, such as serotonin and norepinephrine, which are
in your brain.</p>
<p><a name="INV-c2c555ef-4792-4e3d-8d7e-1cc13b2b539a" id=
"INV-c2c555ef-4792-4e3d-8d7e-1cc13b2b539a"></a><span class=
"Bold">Who should not take nefazodone?</span></p>
<p><a name="INV-4fc14826-25c1-443b-9da6-71304caed0ed" id=
"INV-4fc14826-25c1-443b-9da6-71304caed0ed"></a>Do <span class=
"Bold"><span class="Italics">not</span></span> take nefazodone if
you</p>
<ul class="Disc">
<li>are allergic to nefazodone or the related medicine
Desyrel<span class="Sup">®</span> (trazodone).</li>
<li>are taking Seldane<span class="Sup">®</span> (terfenadine), an
antihistamine; Hismanal<span class="Sup">®</span> (astemizole), an
antihistamine; Propulsid<span class="Sup">®</span> (cisapride),
used for heartburn; Halcion<span class="Sup">®</span> (triazolam),
used for insomnia; Orap<span class="Sup">®</span> (pimozide), used
to treat Tourette’s syndrome; or Tegretol<span class="Sup">®</span>
(carbamazepine), used to control seizures.</li>
<li>currently have liver problems.</li>
<li>are taking or have taken within the last 14 days one of the
medicines for depression known as monoamine oxidase inhibitors
(MAOIs), such as Nardil® or Parnate®.</li>
</ul>
<p><a name="INV-0e4701be-062b-4605-8c7a-cd92414a26fb" id=
"INV-0e4701be-062b-4605-8c7a-cd92414a26fb"></a>Be sure to tell your
doctor if you</p>
<ul class="Disc">
<li>have ever had liver problems;</li>
<li>are taking <span class="Bold"><span class=
"Italics">any</span></span> other medicine, vitamin supplement, or
herbal remedy, including those sold without a prescription
(over-the-counter);</li>
<li>have heart problems or have had a heart attack or stroke;</li>
<li>have had manic episodes (extreme agitation or
excitability);</li>
<li>have ever attempted suicide;</li>
<li>have had convulsions (seizures);</li>
<li>are pregnant or breast-feeding.</li>
</ul>
<p><a name="INV-c556714d-c496-463d-a6e2-d373ef8e56e3" id=
"INV-c556714d-c496-463d-a6e2-d373ef8e56e3"></a><span class=
"Bold">How should I take nefazodone?</span></p>
<ul class="Disc">
<li>Take nefazodone at the same time every day exactly as
prescribed by your doctor. You may take nefazodone with or without
food.</li>
<li>It may take a while for you to feel that nefazodone is working.
You may not feel the full effect for several weeks. Once you feel
better, it is important to keep taking nefazodone as directed by
your doctor.</li>
<li>If you miss a dose of nefazodone, skip that dose and continue
with your regular schedule. Never take 2 doses at the same
time.</li>
<li>If you think that you have taken more nefazodone than
prescribed, contact your doctor, local poison control center, or
emergency room right away.</li>
</ul>
<p><a name="INV-aaed8242-4c88-490f-8d2f-184bb3398197" id=
"INV-aaed8242-4c88-490f-8d2f-184bb3398197"></a><span class=
"Bold">What should I avoid while taking nefazodone?</span></p>
<ul class="Disc">
<li>Do not drive or operate possibly dangerous machinery (such as
an automobile, power mower, or power tool) or participate in any
hazardous activity that requires full mental alertness until you
know how nefazodone affects you.</li>
<li>Before taking nefazodone, tell your doctor about any medicines
you are taking, including vitamin supplements, herbal remedies, and
any non-prescription (over-the-counter) medicines. Some of these
medicines may affect how nefazodone works and should not be used in
combination without talking to your doctor.</li>
<li>Do not drink alcoholic beverages while taking nefazodone.</li>
<li>Tell your doctor if you are pregnant, planning to become
pregnant, or become pregnant while taking nefazodone. It is not
known whether nefazodone can harm your unborn baby.</li>
<li>Talk with your doctor before taking nefazodone if you are
breast-feeding. It is not known whether nefazodone can pass through
your breast milk to the baby.</li>
</ul>
<p><a name="INV-212445ae-4f5d-49e2-ad4f-9b3c2b3cca58" id=
"INV-212445ae-4f5d-49e2-ad4f-9b3c2b3cca58"></a><span class=
"Bold">What are the possible side effects of nefazodone?</span></p>
<p><a name="INV-e3ad3d0f-4a94-47b4-bf57-26c72f80a390" id=
"INV-e3ad3d0f-4a94-47b4-bf57-26c72f80a390"></a>The most common side
effects of nefazodone are sleepiness, dry mouth, nausea, dizziness,
constipation, weakness, lightheadedness, problems with vision, and
confusion.</p>
<p><a name="INV-d123a107-d9d2-4554-8dbd-5abf708ef2f5" id=
"INV-d123a107-d9d2-4554-8dbd-5abf708ef2f5"></a>Call your doctor for
medical for medical advice about side effects. You may report side
effects to FDA 1-800-FDA-1088.</p>
<p><a name="INV-20802abb-cb4e-42e3-b5f5-2ea7b5c65c4d" id=
"INV-20802abb-cb4e-42e3-b5f5-2ea7b5c65c4d"></a><span class=
"Bold">Call your doctor right away if you have any of the following
side effects:</span></p>
<ul class="Disc">
<li>Yellowing of the skin or whites of eyes (jaundice)</li>
<li>Unusually dark urine</li>
<li>Loss of appetite that lasts several days or longer</li>
<li>Severe nausea</li>
<li>Abdominal (lower stomach) pain</li>
<li>Rash or hives</li>
<li>Seizure (convulsion)</li>
<li>Fainting</li>
<li>Erection that lasts too long</li>
</ul>
<p><a name="INV-304df1f0-2b84-40bb-8165-d0d4fe153171" id=
"INV-304df1f0-2b84-40bb-8165-d0d4fe153171"></a>Tell your doctor
right away about any side effects that you have or discomfort that
you experience. Do not change your dose or stop taking nefazodone
without talking with your doctor first.</p>
<p><a name="INV-3bbd39f2-6a81-444f-a2ad-d016a081bf3d" id=
"INV-3bbd39f2-6a81-444f-a2ad-d016a081bf3d"></a>Medicines are
sometimes prescribed for conditions that are not mentioned in
patient information leaflets. Your doctor has prescribed nefazodone
for you and you alone. Do not give nefazodone to other people even
if they have the same condition. It may harm them.</p>
<p><a name="INV-411716fb-84d0-4268-8598-5aa9befae82d" id=
"INV-411716fb-84d0-4268-8598-5aa9befae82d"></a>This leaflet
provides a summary of the most important information about
nefazodone. If you would like more information, talk with your
doctor or pharmacist. You can ask for information about nefazodone
that is written for healthcare professionals.</p>
<p><a name="INV-028c652f-bb90-4ad6-aea6-7a01487d4a38" id=
"INV-028c652f-bb90-4ad6-aea6-7a01487d4a38"></a>Seldane<span class=
"Sup">®</span> is a registered trademark of Hoechst Marion Roussel
Inc. (now Aventis Pharmaceuticals).</p>
<p><a name="INV-16488a24-f7e6-4d82-883e-ec352f51844d" id=
"INV-16488a24-f7e6-4d82-883e-ec352f51844d"></a>Hismanal<span class=
"Sup">®</span> and Propulsid<span class="Sup">®</span> are
registered trademarks of Janssen Pharmaceutica Products, L.P.</p>
<p><a name="INV-50b7d714-bbce-4a7a-a970-1481b33d945f" id=
"INV-50b7d714-bbce-4a7a-a970-1481b33d945f"></a>Nardil<span class=
"Sup">®</span> is a registered trademark of Parke-Davis.</p>
<p><a name="INV-907123ee-e777-494e-96ee-bb3c115de9ea" id=
"INV-907123ee-e777-494e-96ee-bb3c115de9ea"></a>Parnate<span class=
"Sup">®</span> is a registered trademark of SmithKline Beecham
Pharmaceuticals.</p>
<p><a name="INV-e14ee232-422b-4217-bdd4-7f9718a76723" id=
"INV-e14ee232-422b-4217-bdd4-7f9718a76723"></a>Halcion<span class=
"Sup">®</span> is a registered trademark of Pharmacia &amp;
Upjohn.</p>
<p><a name="INV-0bf8ad4b-96b1-43eb-8f2a-35f1ce028fb8" id=
"INV-0bf8ad4b-96b1-43eb-8f2a-35f1ce028fb8"></a>Orap<span class=
"Sup">®</span> is a registered trademark of Gate Pharmaceuticals, a
division of TEVA Pharmaceuticals USA.</p>
<p><a name="INV-1778a3cc-b279-4c68-ad09-95a50a1b619d" id=
"INV-1778a3cc-b279-4c68-ad09-95a50a1b619d"></a>Tegretol<span class=
"Sup">®</span> is a registered trademark of Novartis
Pharmaceuticals Corporation.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">MEDICATION GUIDE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42231-1"><a name="INV-e76514f7-515c-4141-b2d8-87ddc729d630" id=
"INV-e76514f7-515c-4141-b2d8-87ddc729d630"></a> <a name=
"section-17" id="section-17"></a>
<p class="First"><a name="INV-a30efe2a-9300-455f-962f-cb27c27e12c1"
id="INV-a30efe2a-9300-455f-962f-cb27c27e12c1"></a><span class=
"Bold">NEFAZODONE HYDROCHLORIDE TABLETS, USP</span></p>
<p><a name="INV-aada9e8f-3bc1-4dd2-b5bb-e754287b3e30" id=
"INV-aada9e8f-3bc1-4dd2-b5bb-e754287b3e30"></a><span class=
"Bold">Antidepressant Medicines, Depression and other Serious
Mental Illnesses, and Suicidal Thoughts or Actions</span></p>
<p><a name="INV-63347863-e594-42ab-8c12-2e5444dbfc88" id=
"INV-63347863-e594-42ab-8c12-2e5444dbfc88"></a>Read the Medication
Guide that comes with you or your family member’s antidepressant
medicine. This Medication Guide is only about the risk of suicidal
thoughts and actions with antidepressant medicines. <span class=
"Bold">Talk to your, or your family member’s, healthcare provider
about:-</span></p>
<p><a name="INV-c25cf9dd-1288-4019-a629-b6a8c4f2e4b5" id=
"INV-c25cf9dd-1288-4019-a629-b6a8c4f2e4b5"></a>• all risks and
benefits of treatment with antidepressant medicines</p>
<p><a name="INV-5d05e1a0-0c6d-4985-8c8f-be84b6ca25af" id=
"INV-5d05e1a0-0c6d-4985-8c8f-be84b6ca25af"></a>• all treatment
choices for depression or other serious mental illness</p>
<p><a name="INV-f12c8c0e-24f4-4f9c-9603-f3e8d0400a87" id=
"INV-f12c8c0e-24f4-4f9c-9603-f3e8d0400a87"></a><span class=
"Bold">What is the most important information I should know about
antidepressant medicines, depression and other serious mental
illnesses, and suicidal thoughts or actions?</span></p>
<p><a name="INV-36991c63-e69c-4395-841e-3b59697ea0c7" id=
"INV-36991c63-e69c-4395-841e-3b59697ea0c7"></a><span class=
"Bold">1. Antidepressant medicines may increase suicidal thoughts
or actions in some children, teenagers, and young adults within the
first few months of treatment.</span></p>
<p><a name="INV-20f1eb1a-24f7-493f-ba2d-f964daa9a6ec" id=
"INV-20f1eb1a-24f7-493f-ba2d-f964daa9a6ec"></a>2. <span class=
"Bold">Depression and other serious mental illnesses are the most
important causes of suicidal thoughts and actions. Some people may
have a particularly high risk of having suicidal thoughts or
actions.</span> These include people who have (or have a family
history of) bipolar illness (also called manic-depressive illness)
or suicidal thoughts or actions.</p>
<p><a name="INV-79bd6b18-d961-4acb-a689-ac831da3530c" id=
"INV-79bd6b18-d961-4acb-a689-ac831da3530c"></a><span class=
"Bold">3. How can I watch for and try to prevent suicidal thoughts
and actions in myself or a family member?</span></p>
<p><a name="INV-ed592e75-71f1-47ee-89d6-690dcb4c8b83" id=
"INV-ed592e75-71f1-47ee-89d6-690dcb4c8b83"></a>• Pay close
attention to any changes, especially sudden changes, in mood,
behaviors, thoughts, or feelings. This is very important when an
antidepressant medicine is started or when the dose is changed.</p>
<p><a name="INV-c294a7b6-dd6b-427a-98bc-eb3f63dc6d68" id=
"INV-c294a7b6-dd6b-427a-98bc-eb3f63dc6d68"></a>• Call the
healthcare provider right away to report new or sudden changes in
mood, behavior, thoughts, or feelings.</p>
<p><a name="INV-a6b601c5-ecaa-47ec-ba62-29c643f09c38" id=
"INV-a6b601c5-ecaa-47ec-ba62-29c643f09c38"></a>• Keep all follow-up
visits with the healthcare provider as scheduled. Call the
healthcare provider between visits as needed, especially if you
have concerns about symptoms.</p>
<p><a name="INV-e45a9aa4-cfe7-447f-a69b-5f5600ad5489" id=
"INV-e45a9aa4-cfe7-447f-a69b-5f5600ad5489"></a><span class=
"Bold">Call a healthcare provider right away if you or your family
member has any of the following symptoms, especially if they are
new, worse, or worry you:</span></p>
<p><a name="INV-5a7cdde7-b077-4e41-bd3f-f2ab26a65626" id=
"INV-5a7cdde7-b077-4e41-bd3f-f2ab26a65626"></a>• thoughts about
suicide or dying</p>
<p><a name="INV-55fc56d2-d4b0-4b24-9bb2-db9e461f6b8d" id=
"INV-55fc56d2-d4b0-4b24-9bb2-db9e461f6b8d"></a>• attempts to commit
suicide</p>
<p><a name="INV-ba160349-5b01-4435-9952-2c0a914c1e82" id=
"INV-ba160349-5b01-4435-9952-2c0a914c1e82"></a>• new or worse
depression</p>
<p><a name="INV-bac18381-0883-4ea9-94ed-f86f47d35f01" id=
"INV-bac18381-0883-4ea9-94ed-f86f47d35f01"></a>• new or worse
anxiety</p>
<p><a name="INV-5b3c5442-08e6-4bfd-86cf-c3442f321ce9" id=
"INV-5b3c5442-08e6-4bfd-86cf-c3442f321ce9"></a>• feeling very
agitated or restless</p>
<p><a name="INV-1d81fcaf-88cf-4543-ad42-4dcbe602d854" id=
"INV-1d81fcaf-88cf-4543-ad42-4dcbe602d854"></a>• panic attacks</p>
<p><a name="INV-a13cef07-1e88-44cd-adde-3c37fb6fba04" id=
"INV-a13cef07-1e88-44cd-adde-3c37fb6fba04"></a>• trouble sleeping
(insomnia)</p>
<p><a name="INV-195a9f66-81d2-48db-9f79-99306b5f943d" id=
"INV-195a9f66-81d2-48db-9f79-99306b5f943d"></a>• new or worse
irritability</p>
<p><a name="INV-a2212de3-41cf-45ca-99ab-58e1c3017833" id=
"INV-a2212de3-41cf-45ca-99ab-58e1c3017833"></a>• acting aggressive,
being angry, or violent</p>
<p><a name="INV-8b4bdfe8-9c52-4a12-ace7-46d3b1d35b5f" id=
"INV-8b4bdfe8-9c52-4a12-ace7-46d3b1d35b5f"></a>• acting on
dangerous impulses</p>
<p><a name="INV-19dfa754-18e0-4476-8ad9-466c31a3f03f" id=
"INV-19dfa754-18e0-4476-8ad9-466c31a3f03f"></a>• an extreme
increase in activity and talking (mania)</p>
<p><a name="INV-4377465f-71e1-4847-92b7-fa82b93ab72a" id=
"INV-4377465f-71e1-4847-92b7-fa82b93ab72a"></a>• other unusual
changes in behavior or mood</p>
<p><a name="INV-7522e2d6-c962-49c9-a787-8896e870a5bf" id=
"INV-7522e2d6-c962-49c9-a787-8896e870a5bf"></a><span class=
"Bold">What else do I need to know about antidepressant
medicines?</span></p>
<p><a name="INV-246778c4-1522-45d4-9c6a-5b273d76fe93" id=
"INV-246778c4-1522-45d4-9c6a-5b273d76fe93"></a>• <span class=
"Bold">Never stop an antidepressant medicine without first talking
to a healthcare provider.</span> Stopping an antidepressant
medicine suddenly can cause other symptoms.</p>
<p><a name="INV-c70cd194-885a-4703-8695-ba500a9cf96a" id=
"INV-c70cd194-885a-4703-8695-ba500a9cf96a"></a>• <span class=
"Bold">Antidepressants are medicines used to treat depression and
other illnesses.</span> It is important to discuss all the risks of
treating depression and also the risks of not treating it. Patients
and their families or other caregivers should discuss all treatment
choices with the healthcare provider, not just the use of
antidepressants.</p>
<p><a name="INV-a693834c-712d-4b4c-a3dd-3b3b171b47c3" id=
"INV-a693834c-712d-4b4c-a3dd-3b3b171b47c3"></a>• <span class=
"Bold">Antidepressant medicines have other side effects.</span>
Talk to the healthcare provider about the side effects of the
medicine prescribed for you or your family member.</p>
<p><a name="INV-e30788dc-5edd-4832-906f-d2450ce651bf" id=
"INV-e30788dc-5edd-4832-906f-d2450ce651bf"></a>• <span class=
"Bold">Antidepressant medicines can interact with other
medicines.</span> Know all of the medicines that you or your family
member takes. Keep a list of all medicines to show the healthcare
provider. Do not start new medicines without first checking with
your healthcare provider.</p>
<p><a name="INV-7a0f66be-2393-4733-af1e-69b27d0f64a3" id=
"INV-7a0f66be-2393-4733-af1e-69b27d0f64a3"></a>• <span class=
"Bold">Not all antidepressant medicines prescribed for children are
FDA approved for use in children.</span> Talk to your child’s
healthcare provider for more information.</p>
<p><a name="INV-0cc5cfe5-3de0-469e-8b67-54815bf21e45" id=
"INV-0cc5cfe5-3de0-469e-8b67-54815bf21e45"></a>This Medication
Guide has been approved by the U.S. Food and Drug Administration
for all antidepressants.</p>
<p><a name="INV-de34f946-b1d1-4f5d-a38b-4d308c4f40af" id=
"INV-de34f946-b1d1-4f5d-a38b-4d308c4f40af"></a>Manufactured
for:</p>
<p><a name="INV-15448043-5b5b-437f-a452-f30a5d3143ab" id=
"INV-15448043-5b5b-437f-a452-f30a5d3143ab"></a>Ranbaxy
Pharmaceutical Inc.</p>
<p><a name="INV-f0448332-74ba-495b-b430-c65c44d0c80b" id=
"INV-f0448332-74ba-495b-b430-c65c44d0c80b"></a>Jacksonville FL,
32257 USA</p>
<p><a name="INV-e9f6ab77-b607-4db9-998b-53c1a277aa76" id=
"INV-e9f6ab77-b607-4db9-998b-53c1a277aa76"></a>by: Ranbaxy
Laboratories Limited</p>
<p><a name="INV-dbf52a08-4a16-4e76-bb1e-c45f3e3dc21e" id=
"INV-dbf52a08-4a16-4e76-bb1e-c45f3e3dc21e"></a>New Delhi – 110 019,
India</p>
<p><a name="INV-209d0854-e283-4748-be11-21031a3409c4" id=
"INV-209d0854-e283-4748-be11-21031a3409c4"></a>December 2008</p>
<p><a name="INV-186ab3cd-5e45-4924-a6de-708b4af1da12" id=
"INV-186ab3cd-5e45-4924-a6de-708b4af1da12"></a></p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>NEFAZODONE
HYDROCHLORIDE</strong><br>
<span class="contentTableReg">nefazodone hydrochloride
tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-541</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Nefazodone hydrochloride</strong>
(UNII: 27X63J94GR) (nefazodone - UNII:59H4FCV1TF)</td>
<td class="formItem"></td>
<td class="formItem">50 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide (red and/or
yellow)</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium starch glycolate</strong>
()</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink (light)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX541</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:63304-541-30</td>
<td class="formItem">30 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:63304-541-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>NEFAZODONE
HYDROCHLORIDE</strong><br>
<span class="contentTableReg">nefazodone hydrochloride
tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-542</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Nefazodone hydrochloride</strong>
(UNII: 27X63J94GR) (nefazodone - UNII:59H4FCV1TF)</td>
<td class="formItem"></td>
<td class="formItem">100 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate</strong>
()</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX542</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:63304-542-30</td>
<td class="formItem">30 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:63304-542-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>NEFAZODONE
HYDROCHLORIDE</strong><br>
<span class="contentTableReg">nefazodone hydrochloride
tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-543</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Nefazodone hydrochloride</strong>
(UNII: 27X63J94GR) (nefazodone - UNII:59H4FCV1TF)</td>
<td class="formItem"></td>
<td class="formItem">150 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide (red and/or
yellow)</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium starch glycolate</strong>
()</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown (peach)</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX543</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:63304-543-30</td>
<td class="formItem">30 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:63304-543-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>NEFAZODONE
HYDROCHLORIDE</strong><br>
<span class="contentTableReg">nefazodone hydrochloride
tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-544</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Nefazodone hydrochloride</strong>
(UNII: 27X63J94GR) (nefazodone - UNII:59H4FCV1TF)</td>
<td class="formItem"></td>
<td class="formItem">200 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide (red and/or
yellow)</strong> ()</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium starch glycolate</strong>
()</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (light)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX544</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:63304-544-30</td>
<td class="formItem">30 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:63304-544-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>NEFAZODONE
HYDROCHLORIDE</strong><br>
<span class="contentTableReg">nefazodone hydrochloride
tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-545</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Nefazodone hydrochloride</strong>
(UNII: 27X63J94GR) (nefazodone - UNII:59H4FCV1TF)</td>
<td class="formItem"></td>
<td class="formItem">250 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong>
(UNII: ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate</strong>
()</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX545</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:63304-545-30</td>
<td class="formItem">30 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:63304-545-05</td>
<td class="formItem">500 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer"></td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Ranbaxy Pharmaceuticals
Inc.</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="#boxedwarning" target="_blank">Boxed Warnings</a>,
<a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22nefazodone%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=nefazodone"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=nefazodone"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00402&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">NEFAZODONE HYDROCHLORIDE- nefazodone
hydrochloride tablet<br></h3>
<h4>Number of versions: 1</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Mar 13, 2009</td>
<td>1 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=10220">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">NEFAZODONE HYDROCHLORIDE- nefazodone
hydrochloride tablet<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098649">1098649</a></td>
<td>nefazodone HCl 100 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098649">1098649</a></td>
<td>Nefazodone hydrochloride 100 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098666">1098666</a></td>
<td>nefazodone HCl 150 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098666">1098666</a></td>
<td>Nefazodone hydrochloride 150 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098670">1098670</a></td>
<td>nefazodone HCl 200 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098670">1098670</a></td>
<td>Nefazodone hydrochloride 200 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098674">1098674</a></td>
<td>nefazodone HCl 250 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098674">1098674</a></td>
<td>Nefazodone hydrochloride 250 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>9</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098678">1098678</a></td>
<td>nefazodone HCl 50 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>10</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=1098678">1098678</a></td>
<td>Nefazodone hydrochloride 50 MG Oral Tablet</td>
<td>SCD</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">NEFAZODONE HYDROCHLORIDE- nefazodone
hydrochloride tablet<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=b1d149db-ad43-4f3f-aef1-fb0395ba4191</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ANEFAZODONE%20HYDROCHLORIDE%2D%20Nefazodone%20Hydrochloride%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Db1d149db%2Dad43%2D4f3f%2Daef1%2Dfb0395ba4191%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "NEFAZODONE HYDROCHLORIDE- nefazodone hydrochloride tablet <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
